



PATENT (fw)

ATTORNEY DOCKET NO. 50635/002001

Certificate of Mailing: Date of Deposit: February 2, 2009

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Katherine M. Johnson
Printed name of person mailing correspondence

Katherine M. Johnson
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Olli Vuolteenaho et al.	Confirmation No.:	9413
Serial No.:	10/562,081	Art Unit:	1647
Filed:	April 5, 2006	Examiner:	Shulamith H. Shafer
Customer No.:	21559		
Title:	Assay		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF CERTIFIED COPY OF PRIORITY DOCUMENT


Transmitted herewith in connection with the above-captioned patent application is a certified copy of United Kingdom application number 0315291.5, filed on June 30, 2003. This transmission is made in support of an earlier made priority claim to United Kingdom application number 0315291.5. The application also claims priority to PCT/EP04/06971. If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: February 2, 2009

Susan M. Michaud
Susan M. Michaud, Ph.D.
Reg. No. 42,885

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with patent application GB0315291.5 filed on 30 June 2003.

I also certify that the application is now proceeding in the name as identified herein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.


In accordance with the rules, the words "public limited company" may be replaced by p.l.c., L.C. or PLC.

Registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed




Dated 4 December 2008



The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

Statement of inventorship and of right to grant of a patent

1. Your reference	P88837	
2. Patent application number <i>(If you know it)</i>	0315291.5	30 JUN 2003
3. Full name of the or of each applicant	ORION CORPORATION Orioninte 1 FIN-02200 Espoo FINLAND	
4. Title of the invention	ASSAY	
5. State how the applicant(s) derived the right from the inventor(s) to be granted a patent	Vuolteenaho, Hirvinen, Ruskoaho and Leppaluoto - by agreement Haapalahti - by employment	
6. How many, if any, additional Patents Forms 7/77 are attached to this form? <i>(see note (c))</i>	5	
7.	<p>I/We believe that the person(s) named over the page (and on any extra copies of this form) is/are the inventor(s) of the invention which the above patent application relates to.</p> <p>Signature  Date 30 JUNE 2003 J.A. KEMP & CO.</p>	
8. Name and daytime telephone number of person to contact in the United Kingdom	JANE SEXTON 020 7405 3292	

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there are more than three inventors, please write the names and addresses of the other inventors on the back of another Patents Form 7/77 and attach it to this form.
- When an application does not declare any priority, or declares priority from an earlier UK application, you must provide enough copies of this form so that the Patent Office can send one to each inventor who is not an applicant.
- Once you have filled in the form you must remember to sign and date it.

Patents Form 7/77

Enter the full names, addresses and postcodes of the inventors in the boxes and underline the surnames

Olli Vuolteenaho
Kelokuusentie 8
FIN-90240 Oulu
FINLAND

Patents ADP number (if you know it): 8663809001

Minna Hirvinen
Vesalankuja 4 B 10
FIN-90420 Oulu
FINLAND

Patents ADP number (if you know it): 8663817001

Heikki Ruskoaho
Joonantie 10
FIN-91800 Tyrnävä
FINLAND

Patents ADP number (if you know it): 8663825001

Reminder

Have you signed the form?

Enter the full names, addresses and postcodes of the inventors in the boxes and underline the surnames

Juhani Leppaluoto
Rantakatu 10 A
FIN-90100 Oulu
FINLAND

Patents ADP number (if you know it): 8663783001

Jouko Haapalahti
Koykkyrintie 28
90450 Kempele
FINLAND

Patents ADP number (if you know it): 8663791001

Reminder

Have you signed the form?

Patents ADP number (if you know it):



INVESTOR IN PEOPLE


GB 0315291.5

By virtue of a direction given under Section 30 of the Patents Act 1977, the application is proceeding in the name of:

ORION DIAGNOSTICA OY,
Koivu-Mankkaan tie 6B,
FIN-02200 Espoo,
Finland

Incorporated in Finland,

[ADP No. 08792160002]



01JUL03 EB19068-1 D00192
F01/7700 0.00-0315291.5

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference P88837 JHS

2. Patent application number 0315291.5
(The Patent Office will fill in this part) 30 JUN 2003

3. Full name, address and postcode of the or of each applicant (underline all surnames) ORION CORPORATION
Orionintie 1
FIN-02200 Espoo
FINLAND

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation FINLAND

SECTION 30 (1) ACT APPLICATION FILED 29/4/04
85 757 40 5001

4. Title of the invention ASSAY

5. Name of your agent (if you have one) J.A. KEMP & CO.
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode) 14 South Square
Gray's Inn
London
WC1R 5JJ

Patents ADP number (if you know it) 24001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
--	---------	---	--

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)
---	-------------------------------	--

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

Yes

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form	0
Description	59
Claim(s)	8
Abstract	1
Drawing(s)	4

10. If you are also filing any of the following, state how many against each item.

Priority documents	0
Translations of priority documents	0
Statement of inventorship and right to grant of a patent (Patents Form 7/77)	6
Request for preliminary examination and search (Patents Form 9/77)	0
Request for substantive examination (Patents Form 10/77)	0
Any other documents (please specify)	0

11.

I/We request the grant of a patent on the basis of this application.

Signature

J.A. Kemp & Co.

Date 30 JUNE 2003

12. Name and daytime telephone number of person to contact in the United Kingdom

Jane Sexton
020 7405 3292

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

ASSAY

Technical Field of the Invention

The invention relates to test methods useful for the diagnosis and treatment of
5 cardiac conditions such as heart failure and to substances for use in the methods.

Background of the invention

Congestive heart failure (CHF) is a clinical syndrome caused by heart disease,
characterised by breathlessness and abnormal sodium and water retention, and
10 resulting in oedema. This occurs when the heart is unable to generate a cardiac
output sufficient to meet the demands of the body without marked increase of
diastolic pressure. It is a consequence of a cardiac disease which impairs ventricular
systolic or diastolic function, or both. It is not a single disease but the end stage of
many different forms of heart diseases, the most common of which are the coronary
15 artery diseases, hypertension and diabetes (Kannel *et al.* 1994). Heart failure is
manifested by symptoms of poor tissue perfusion (e.g., fatigue, poor exercise
tolerance) or congestion of vascular beds (e.g., dyspnoea, pulmonary oedema,
peripheral oedema) or both. Treatment of heart failure is generally directed towards
its underlying causes.

20 The prevalence of symptomatic heart failure in the general population in
Europe is estimated to be about 0.4-2 %. As the prevalence rises rapidly with age, the
increasing life expectancy is expected to have a major impact on the incidence of
heart failure in the near future. The asymptomatic form of left-ventricular systolic
dysfunction is estimated to be as common as symptomatic congestive heart failure
25 (McDonagh *et al.* 1997).

The current routine clinical and investigative parameters used for the diagnosis
of heart failure (clinical examination, electrocardiography, chest X-ray) have been
found to be inadequate because the diagnosis causes false-positive results (Remes *et*
al. 1991). Echocardiography provides specific diagnostic and prognostic information,
30 but it is not particularly suitable for screening or for rapid point-of-care diagnostics.
Thus, there is a need for new diagnostic tests for cardiac impairment.

A number of studies have demonstrated the usefulness of measurement of

single peptides derived from atrial natriuretic peptide prohormone (proANP) and brain natriuretic peptide prohormone (proBNP) in the diagnosis of heart failure (Talwar *et al.* 2000; De Lemos *et al.* 2001; Daly *et al.* 2002). Cardiac impairment is associated with elevated circulating levels of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), N-terminal fragment of proANP (NT-proANP) and N-terminal fragment of proBNP (NT-proBNP) (Sagnella 1998). High plasma concentrations correlate with poor prognosis after myocardial infarction and heart failure (Omland *et al.* 2002). Moreover, monitoring plasma levels of NT-proBNP appears to offer more powerful guidance in therapy of heart failure than follow-up by conventional clinical parameters (Troughton *et al.* 2000).

However prior art diagnostic methods, such as those disclosed in WO 87/06938, WO 00/35951, WO 91/00292, US 5,786,163, EP 648 228 B1, WO 00/45176, WO 00/19207, US 6,124,430, EP 542 255 B1) or those commercially available, are only intended to measure, and are only capable of measuring, a single peptide (ANP, BNP, NT-proANP or NT-proBNP) at a time. For example, the prior art discloses the use of ANP receptor or NPRA (GC-A) receptor in assays to determine natriuretic peptides, but does not disclose any simultaneous determination of natriuretic peptides. US Patent Number 5,747,274 discloses simultaneous detection of at least three cardiac markers using at least three different monoclonal or polyclonal antibody pairs, each specific for a different marker. Consequently, these assays produce multiple results. Thus there remains in the art a need for a reliable and sensitive but relatively cheap and simple means for detecting or diagnosing cardiac impairment such as heart failure.

Accordingly the present invention provides a test method which detects activation or inactivation of the ANP and BNP hormonal systems by assaying for both proANP- and proBNP- derived peptides simultaneously. The method produces a single result and is simpler to perform than prior art methods. Moreover the present assay methods show greater sensitivity than prior art methods. Further still, the present test has a profound capability to give a reliable test result whether the patient is in an early phase or late phase of heart failure. The single assay format of the present invention, performed simultaneously *per se*, offers a cheaper and more cost effective alternative to the available tests thus allowing reliable measurement of

activation or inactivation of both the ANP and the BNP hormonal systems

Summary of the Invention

Accordingly the present invention provides an *in vitro* method of determining
 5 activation or inactivation of the atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems, the method comprising detecting the presence or amount of atrial and brain natriuretic peptide prohormones (proANP and proBNP) or fragments thereof in a sample.

The invention also provides:

10 - an agent which comprises:

- (a) (i) proANP (SEQ ID NO. 1), ANP (SEQ ID NO. 2) or NT-proANP (SEQ ID NO. 3);
- (ii) a homologous sequence having at least 70% identity to (i); or
- (iii) a fragment of (i) or (ii) which is at least 6 amino acids in

15 length;

and

- (b) (i) pro-BNP (SEQ ID NO. 4), BNP (SEQ ID NO. 5), NT-proBNP (SEQ ID NO. 6);
- (ii) a homologous sequence having at least 70% identity to (i); or
- (iii) a fragment of (i) or (ii) which is at least 6 amino acids in

20

length;

- a polynucleotide comprising sequence which encodes the agent, or complementary sequence:

- an expression vector and host cell comprising the polynucleotide;

25

- a process for producing the polypeptide agent which comprises:

(a) cultivating the host cell under conditions to provide for expression of the polypeptide; and optionally

(b) recovering the expressed polypeptide;

- a method of identifying a substance that binds specifically to

30

- (a) (i) proANP (SEQ ID NO. 1), ANP (SEQ ID NO. 2) or NT-proANP (SEQ ID NO. 3);
- (ii) a homologous sequence having at least 70% identity to (i); or

(iii) a fragment of (i) or (ii) which is at least 6 amino acids in length

and

(b) (i) pro-BNP (SEQ ID NO. 4), BNP (SEQ ID NO. 5), NT-proBNP (SEQ ID NO. 6);

5 (ii) a homologous sequence having at least 70% identity to (i); or

(iii) a fragment of (i) or (ii) which is at least 6 amino acids in length

which method comprises:

(A) contacting a candidate substance with (a) and (b) under conditions which allow specific binding; and

10 (B) determining whether the candidate substance binds to (a) and (b);

- an antibody, fragment or derivative thereof which is able to bind to both:

(a) (i) proANP (SEQ ID NO. 1), ANP (SEQ ID NO. 2) or NT-proANP (SEQ ID NO. 3);

(ii) a homologous sequence having at least 70% identity to (i); or

15 (iii) a fragment of (i) or (ii) which is at least 6 amino acids in length;

and

(b) (i) pro-BNP (SEQ ID NO. 4), BNP (SEQ ID NO. 5) or NT-proBNP (SEQ ID NO. 6);

(ii) a homologous sequence having at least 70% identity to (i); or

20 (iii) a fragment of (i) or (ii) which is at least 6 amino acids in length

- a process for making the antibody;

- a dipstick or ELISA plate comprising the antibody.

The invention further provides methods of diagnosing and/or treating heart failure and a diagnostic kit for use in such methods.

25

Brief Description of the Drawings

Figure 1: Purification by reverse phase HPLC of a novel protein or peptide agent of the invention.

Figure 2: A competitive binding curve for immunoassay of NT-proXNP.

30 Figure 3: Serum levels of NT-proANP, NT-proBNP and NT-proXNP in patients with cardiac disorders.

Figure 4: Serum levels of NT-proANP, NT-proBNP and NT-proXNP in

cardiac patients.

Figure 5: Response of plasma NT-proANP, NT-proBNP and NT-proXNP and cardiac output (CO) in patients of heart failure to therapy.

5 Brief Description of the Sequences

	SEQ ID NO: 1	amino acid sequence of human proANP
	SEQ ID NO: 2	amino acid sequence of human ANP
	SEQ ID NO: 3	amino acid sequence of human NT-proANP
	SEQ ID NO: 4	amino acid sequence of human proBNP
10	SEQ ID NO: 5	amino acid sequence of human BNP
	SEQ ID NO: 6	amino acid sequence of human NT-proBNP
	SEQ ID NO: 7	nucleotide sequence encoding human proANP
	SEQ ID NO: 8	nucleotide sequence encoding human ANP
	SEQ ID NO: 9	nucleotide sequence encoding human NT-proANP
15	SEQ ID NO: 10	nucleotide sequence encoding human proBNP
	SEQ ID NO: 11	nucleotide sequence encoding human BNP
	SEQ ID NO: 12	nucleotide sequence encoding human NT-proBNP
	SEQ ID NO: 13	amino acid sequence of an agent according to the invention NT-proXNP1
20	SEQ ID NO: 14	amino acid sequence of an agent according to the invention NT-proXNP2
	SEQ ID NO: 15	amino acid sequence of an agent according to the invention NT-proXNP3
	SEQ ID NO: 16	amino acid spacer sequence
25	SEQ ID NO: 17	amino acid sequence of an agent according to the invention NT-proXNP4
	SEQ ID NO: 18	nucleotide sequence encoding NT-proXNP1
	SEQ ID NO: 19	nucleotide sequence encoding NT-proXNP2
	SEQ ID NO: 20	nucleotide sequence encoding NT-proXNP3
30	SEQ ID NO: 21	nucleotide sequence encoding NT-proXNP4
	SEQ ID NO: 22	primer sequence
	SEQ ID NO: 23	primer sequence

	SEQ ID NO: 24	primer sequence
	SEQ ID NO: 25	primer sequence
	SEQ ID NO: 26	primer sequence
	SEQ ID NO: 27	amino acid sequence of human GC-A receptor
5	SEQ ID NO: 28	amino acid sequence of extracellular domain of human GC-A receptor
	SEQ ID NO: 29	amino acid sequence of human GC-B receptor
	SEQ ID NO: 30	amino acid sequence of human GC-C receptor

10

Detailed Description of the Invention

The present invention relates to a new test method which is useful for diagnosing and treating cardiac disease, in particular heart failure and to components and kits for use in the method. The method allows the detection of activation or inactivation of the atrial natriuretic peptide (ANP) hormonal system and the brain natriuretic peptide (BNP) hormonal system in an individual simultaneously. In general the method assays simultaneously for the presence and/or amount of peptides derived from A- and B-type natriuretic peptide prohormones in a suitable biological sample obtained from the individual.

20 *Terms and abbreviations*

proANP is atrial natriuretic peptide prohormone;

proANP is processed by cleavage of the N-terminal fragment into the mature atrial natriuretic peptide (ANP). Human proANP has 126 amino acids (proANP₁₋₁₂₆)

SEQ ID NO:1

25 NPMYNAVSNA DLMDFKNLLD HLEEKMPLED EVVPPQVLSE
PNEEAGAALS PLPEVPPWTG EVSPAQRDGG ALGRGPWDSS
DRSALLKSKL RALLTAPRSL RRSSCFGGRM DRIGAQSGLG CNSFRY

ANP is atrial natriuretic peptide

30 Human ANP is formed by amino acids 99 to 126 of the prohormone (proANP₉₉₋₁₂₆)

SEQ ID NO:2

SLRRSSCFGG RMDRIGAQSG LGCNSFRY

NT-proANP is the N-terminal fragment of proANP

The N-terminal fragment of human proANP is formed by amino acids 1 to 98 (proANP₁₋₉₈)

5 SEQ ID NO:3

NPMYNAVSNA DLMDFKNLLD HLEEKMPLED EVVPPQVLSE
PNEEAGAALS PLPEVPPWTG EVSPAQRDGG ALGRGPWDSS DRSALLKSKL
RALLTAPR

10 ProBNP is brain natriuretic peptide prohormone,

proBNP is processed by cleavage of the N-terminal fragment into the mature brain natriuretic peptide (BNP). Human proBNP has 108 amino acids (proBNP₁₋₁₀₈)

SEQ ID NO:4

HPLGSPGSAS DLETSGLQEQ RNHLQGKLSE LQVEQTSLEP LQESPRPTGV
15 WKSREVATEG IRGHRKMVLY TLRAPRSPKM VQSGSGCFGRK MDRISSSSGL
GCKVLR RH

BNP is brain natriuretic peptide

Human BNP is formed by amino acids 77 to 108 of the prohormone (proBNP₇₇₋₁₀₈)

20 SEQ ID NO:5

SPKMVQSGSGC FGRKMDRISS SSGLGCKVLR RH

NT-proBNP is the N-terminal fragment of proBNP

The N-terminal fragment of human proBNP is formed by amino acids 1 to 76 (proBNP₁₋₇₆)

25 SEQ ID NO:6

HPLGSPGSAS DLETSGLQEQ RNHLQGKLSE LQVEQTSLEP LQESPRPTGV
WKSREVATEG IRGHRKMVLY TLRAPR

30 proXNP is an agent of the invention which comprises amino acid sequence derived or originating from both proANP and proBNP

XNP is an agent of the invention which comprises amino acid sequence derived or originating from both ANP and BNP

NT-proXNP is an agent of the invention which comprises amino acid sequence derived or originating from both NT-proANP and NT-proBNP

NT-proXNP1 is an agent of the invention formed from proBNP₁₅₋₂₄ and proANP₈₂₋₉₆

NT-proXNP2 is an agent of the invention formed from proBNP₁₋₃₇ and proANP₂₉₋₉₈

5 NT-proXNP3 is an agent of the invention formed from proBNP₁₀₋₂₉ or a subsequence thereof and proANP₂₀₋₈₀ or a subsequence thereof

NT-proXNP4 is an agent of the invention formed from proBNP₁₋₇₆ and proANP₁₋₉₈

Variant polypeptides

10 Variants of polypeptides are referred to herein. For example, references are made to variants of proANP, ANP, NT-proANP, proBNP, BNP and NT-proBNP, in the description of binding substances and agents of the invention. Reference is also made to variants of the GC-A, GC-B and GC-C receptor polypeptides.

The term "variant" refers to a polypeptide which has the same essential character as or a basic biological functionality of the relevant polypeptide. Thus a
15 variant is typically capable of complementing one or more activities of that polypeptide. Typically a variant comprises an amino acid sequence which is homologous to all or a part of the sequence of the polypeptide. In general a, (homologous) variant has an amino acid sequence with more than 70% identity, preferably at least 75% or 80% or at least 90% and particularly preferably at least
20 95%, at least 97% or at least 99% identity with the given sequence, for example over a region of at least 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400 or more contiguous amino acids. Variants may include allelic variants, species homologues and the deletion, modification or addition of single amino acids or groups of amino acids within the protein sequence, as long as the peptide maintains a basic biological
25 functionality of the subject polypeptide.

An allelic variant will be a variant which will occur naturally, for example, in a human, and which will function in a substantially similar manner to the relevant polypeptide. Similarly, a species homologue of a protein will be the equivalent protein which occurs naturally in another species and which retains a basic biological
30 function of the given polypeptide. Thus, for example, a naturally occurring or native polypeptide variant, such as those which may be detected in a biological sample, may be an allelic variant or species homologue of another known polypeptide.

Allelic variants and species homologues can be obtained, for example, by probing a library made from cells of the appropriate species using a suitable probe, to obtain clones encoding the allelic or species variants. The clones can be manipulated by conventional techniques to generate a polypeptide which can be produced by recombinant or synthetic techniques known *per se*.

Variants may include polypeptides which are longer in length than the relevant polypeptide. A variant may comprise or consist of at least 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 300, 400, amino acids up to for example 500, 1000 or 2000 amino acids.

A variant may be a fusion protein.

Variants may include amino acid substitutions, for example from 1, 2 or 3 to 10, 20 or 30 (or 10, 20, 30 or 40 to 50, 60 or 70) substitutions. The modified polypeptide generally retains the ability to complement one or more of the activities of and/or the antigenic activity of the subject polypeptide. Conservative substitutions may be made, for example according to the following table. Amino acids in the same block of the second column and preferably in the same line in the third column may be substituted for each other.

ALIPHATIC	Non-Polar	G A P
		I L V
	Polar-uncharged	C S T M
		N Q
	Polar-charged	D E
		K R
AROMATIC		H F W Y

Shorter polypeptide sequences or fragments are within the scope of the invention. For example, a peptide of at least 2, 5, 10, 12, 15, 17, 20, 25 amino acids or up to 30, 40, 50, 60, 70, 80, 100, 200, 300, 400 or 500 amino acids in length (depending on the size of the subject polypeptide) is considered to fall within the scope of the invention as long as it demonstrates a basic biological functionality of the subject polypeptide. In particular, but not exclusively, this aspect of the invention

encompasses the situation when the protein is a fragment of the complete protein sequence and may represent a binding site for another molecule or entity, such as a peptide-binding region, or an epitope. Such fragments may or may not retain other functions of the subject polypeptide.

5 Variant polypeptides as referred to herein generally retain a basic biological functionality of the relevant polypeptide. The variant may retain one or more of the native biological activities or functions of the subject polypeptide.

In particular, a variant as referred to herein generally retains one or more of the binding characteristics of the relevant polypeptide. Alternatively or additionally,
10 the variant may retain an antigenic activity of the polypeptide.

Preferably a variant exhibits at least one of the binding or recognition properties of the subject polypeptide. In particular a variant may be capable of binding to a product that can bind to the polypeptide e.g. a ligand, a receptor or an antibody. Thus, for example, a variant of ANP or BNP may be capable of binding to
15 the GC-A receptor. Similarly, a variant of the GC-A or GC-B receptor may bind ANP or BNP. Typically a variant binds the product with an affinity that is at least 60%, such as at least 70, 80 or 90%, for example 95, 97 or 99% of the affinity with which the relevant polypeptide binds to the product. Suitable binding assays are known in the art.

20 Variants which have a particular activity or binding characteristic of the given polypeptide may be identified based on such activities or characteristics, for example from a library of polypeptides.

In a further embodiment a variant polypeptide may retain the antigenic properties of the subject polypeptide. Such a variant may, for example, be capable of
25 generating an immune response in a subject. The immune response may be antibody and/or cell mediated, such as T-cell mediated. Thus a variant may be capable of raising antibodies which are specific for and bind to the subject polypeptide. A peptide for generating an immune response may be identified by immunisation studies, typically in an animal model. For example, a candidate peptide may be
30 administered to an animal and subsequently the antibody or T-cell response generated which is specific for the peptide may be determined. Antiserum generated following administration of a peptide to an animal may be evaluated for the ability to

bind the peptide or to bind the subject polypeptide.

A variant which has at least one of the binding characteristics of a given polypeptide may comprise at least one binding region of the polypeptide. Such a binding region in general mediates binding of the polypeptide to another product
 5 such as a receptor or an antibody. The binding region may be external or internal to the given polypeptide. Thus a variant may comprise a binding site, epitope or antigenic fragment of the relevant polypeptide. Preferably the binding region in the variant retains the conformation which it has in the relevant polypeptide. Preferably the variants are fragments. For example the fragments may be at least 6 amino acids
 10 in length, preferably at least 10, such as at least 12 or 15 or up to 20, 30 or 40 amino acids. Longer fragments such as up to 60, 90, 100 or 200 amino acids may also be used. Such fragments may not otherwise demonstrate a cellular function or activity of the subject polypeptide.

ANP and BNP

15 Cardiac natriuretic peptides ANP and BNP and the N-terminal fragments (NT-proANP and NT-proBNP) of A- and B-type natriuretic peptide prohormones (proANP and proBNP) are released to the circulation when the heart is subjected to pressure or volume overload. Their function is to decrease the load and protect the heart. In spite of the fact that the heart produces two distinct biologically active
 20 natriuretic peptides (ANP and BNP), each derived from its own gene and regulated differently, their biological effects are mediated to the target cells by a single receptor, GC-A (NPRA) (Drewett *et al.* 1994). Activation of both the ANP and BNP hormonal systems refers to the up-regulation of both ANP and BNP genes or production or increase in plasma concentrations, whereas inactivation of both ANP
 25 and BNP systems refers to the down-regulation of both ANP and BNP genes or production or decrease in plasma concentration.

In cardiac pressure and volume overload, ANP gene expression and the circulating levels of ANP and NT-proANP are primarily induced by increased preload of the heart, whereas BNP gene expression and circulating levels of BNP and
 30 NT-proBNP are primarily sensitive to an increase of afterload (Yoshimura *et al.* 1993; Yasue *et al.* 1994). Moreover, ANP and BNP genes are regulated differentially in the different chambers of the heart (Dzimiri *et al.* 2002). Elevated plasma ANP or

NT-proANP levels are associated with atrial overload e.g. tachycardia, whereas BNP and NT-proBNP are better markers of ventricular overload e.g. aortic stenosis. Markedly elevated circulating levels of both ANP and BNP (and NT-proANP and NT-proBNP) suggest combined atrial and ventricular overload, as in dilated cardiomyopathy. Thus, in physiological and pathophysiological situations the information mediated by ANP and BNP converges in the target cell membrane to cause a common intracellular signalling cascade. As already mentioned existing assays measure one of the analytes at a time (ANP, BNP, NT-proANP or NT-proBNP). Because a major strength of the natriuretic peptides in the diagnosis of cardiac diseases lies in the high negative predictive value, the combination assay of ANP and BNP (or NT-proANP and NT-proBNP) in the present invention will add value over that provided by assaying any of the analytes alone. Sequential assay of ANP and BNP (or NT-proANP and NT-proBNP) would be unnecessarily complex, including doubled effort for quality control, and not as cost-effective.

The present invention provides novel diagnostic methods and use thereof which, by mimicking the physiological regulatory system working in the body, can combine the information obtained from the activation or inactivation, respectively, of the ANP and the BNP hormonal systems by a simple means of simultaneous measurement of a proportionally cumulative concentration of peptides derived from both A- and B-type natriuretic peptide prohormones.

Test methods

The invention provides a new and sensitive method suitable for diagnosing and assessing cardiac conditions such as heart failure, which determines activation or inactivation of the ANP and BNP hormonal systems. The method of the invention focuses on detecting or monitoring the combined levels of proANP, proBNP and fragments thereof in a suitable biological sample. According to the method, peptides derived from or originating from both proANP and proBNP may be assayed at the same time in a given sample.

Peptides derived from proANP and proBNP include NT-proANP, ANP, NT-proBNP, BNP as well as proANP and proBNP. The sample may comprise other peptides also derived from the prohormones eg by proteolysis. For example, other peptides may include proANP₁₋₃₀, proANP₃₁₋₆₇ or proANP₇₉₋₉₈. Thus in one

embodiment, any combination of proANP, NT-proANP, ANP, proBNP, NT-proBNP and BNP, and optionally other derived peptides, may be assayed in the method. In one embodiment the sample may contain proANP-derived peptides without proBNP-derived peptides or vice versa.

5 Since the peptides are detected simultaneously, only a single reading or result is required. The method is suitable for assessing the risk of and detecting cardiac impairment such as heart failure, and for evaluating treatments for heart failure. As such it is more sensitive, cheaper and simpler to perform than prior art methods.

10 The peptides assayed in the invention are present at normal reference levels in the general population. Activation of the ANP and BNP systems may be considered as occurring when the combined peptide level is greater than this normal reference level. Therefore in any particular assay format, if the result indicates a qualitatively or quantitatively higher peptide level than the reference level, activation of the systems is implied. For example, an assay may be calibrated eg using an agent of the
15 invention, so that a particular reading in the assay is known to represent the normal peptide level. Or the assay may be such that a normal or reference level of peptide will produce a negligible or insignificant result.

20 Inactivation of the ANP and BNP systems, for example after heart failure perhaps in response to medical treatment, occurs when the combined peptide level falls from the elevated level associated with the earlier cardiac incident. By performing serial assays it will be possible to detect a qualitative or quantitative decrease in peptide levels. It will be possible to determine also the rate of decrease and so to assess the effectiveness of a given treatment.

25 The present methods are capable of simultaneously detecting both proANP-derived and proBNP-derived peptides. The actual change in individual peptide levels may be for example A+ and B+, A+ and B-, A- and B+, or A- and B- (where A represents levels of proANP- derived peptides and B represents levels of proBNP-derived peptides).

30 The present assay methods may be qualitative or quantitative. For example, a quantitative assay is possible when an agent of the invention is used as a competing antigen in a competition assay.

In general, the present method comprises contacting a sample with a first binding substance which is able to bind both proANP- and proBNP- derived peptides under conditions which will allow such binding to occur. Any binding complexes formed between the first binding substance and such peptides are then detected. Suitable detection means are known in the art and are described in more detail below. The peptides to be detected are as described above. Preferably they are naturally occurring peptides. The peptides provide an indicator of activation or inactivation of the ANP and BNP systems. The first binding substance is as defined herein.

In one preferred embodiment the first binding substance is a bi- or oligo-specific binding substance as defined herein. Such a binding substance is able to bind to both proANP- and proBNP- derived peptides. Preferably this first binding substance is used in the assay when an agent of the invention is not used in the assay, for example as a competing antigen in a competitive binding assay. Binding complexes between the first binding substance and the peptides in the sample may be detected and activation or inactivation determined as above.

In one embodiment, the present method additionally comprises contacting a sample with an agent of the invention as described herein (XNP, proXNP, or NT-proXNP). The agent comprises peptides derived from or originating from both proANP and proBNP and is able to bind to the first binding substance. Such an agent may be used as a standard to calibrate the present assays. The agent may be used as a competing antigen in a competition assay. Peptide levels in a given sample may thus be expressed in terms of agent concentration. Suitable assay formats, detection and quantifying means are known in the art and are described in more detail below.

The methods of the invention are generally applied to a sample, typically a biological sample. Typically the sample is one which is known or suspected of being a body sample from an individual, such as a human. Preferably the sample comprises a body fluid, e.g. blood, serum, plasma, cerebrospinal fluid, urine or saliva. Other biological samples include tissues, cells and tissue culture medium in which peptides derived from A- and B-type natriuretic peptide prohormones might be present. Preferably the sample is a human sample.

A sample may be processed before it is used in the method. For example, it may be diluted, typically in water, saline or saline containing a buffer (any of these diluents may additionally comprise detergent).

Generally, the present method is carried out in aqueous solution. However, in particular embodiments (some of which are discussed below), the first binding substance, or the agent may be immobilised in a solid support. Typically such a support is the surface of the container in which the method is being carried out, such as the surface of a well of a microtitre plate. In other embodiments the support may be a sheet (e.g. a nitrocellulose or nylon sheet) or a bead (e.g. sepharose or latex).

The first binding substance or the agent may be labelled with a detectable label. Examples of suitable labels have been described herein.

In principle, any suitable assay technique may be employed in the present invention. For example, suitable methods include immunoassay methods, both competitive and non-competitive, antibody binding methods employing either unlabelled or labelled antigens or their analogues (immunoassays), or labelled or unlabelled binding substances recognising their antigens or analogues (immunometric assays and receptor binding assays), respectively. Sandwich assays may be used.

Immunoassay methods which may be used include europium fluorescence immunoassays (FIA), enzymelinked immunoabsorbent assays (ELISA), radioimmunoassay (RIA), immunoradiometric assay, enzyme immunoassay, immunoenzymometric assay, time-resolved fluoroimmunoassay, immunofluorometric assay, chemiluminescence immunoassay (CLIA), anodic or cathodic electrochemiluminescence immunoassays, various dry-chemistry test strip assays, particle based immunoassays, direct labelless immunoassays, such as assays based on surface plasmon resonance, surface acoustic waves and surface-enhanced Raman spectroscopy, homogeneous immunoassays such as proximity assays with two different labels, chip technology, array technology, particle enhanced immunoassays and other particle immunoassays, both single and dual size labelled or unlabelled particles. Latex and gold, in different forms, can be mentioned as examples of particles to be used. Turbidometric and nephelometric determinations are also possible assay formats.

Chromatographic membrane technology can also be used as a format to implement the present invention. The chromatographic membrane test comprises both a lateral and flow-through test. The used reagents are either permanently or non-permanently immobilised onto the membrane where they have a very distinct role in the different zones of the test i.e. one or multiple zone(s) for reagent(s), test(s), control(s) etc. The reagents immobilised can be binding substance, the agent of the invention, anti-binding substance antibody, anti-analyte antibody, anti-agent antibody or a label.

Binding complexes of the first binding substance with peptides in the sample or with the agent may be detected using a second binding substance. For example, the second binding substance may be an antibody which itself bears a detectable label such as those listed above. The second binding substance may be a substance that causes precipitation or otherwise immobilises and separates the first binding substance complexes.

Particular embodiments of the present method will now be described in more detail:

(a) One preferred type of method uses labelled proXNP agent as antigen, together with antibody as first binding substance recognising both peptides derived from both A- and B-type natriuretic peptide prohormones and the agent. In such methods a known constant amount of labelled agent is added to the sample containing an unknown amount of unlabelled antigen, i.e. peptide analyte to be measured. Both the labelled and the unlabelled antigen bind to the first binding substance, for example in a competitive manner and measurement of the amount of the bound labelled agent, when compared to the known amount agent added, can be used to determine how much unlabelled antigen is present in the sample thus reflecting the activation or the inactivation of both the ANP and the BNP systems as a proportionally cumulative measure of peptides derived from both A- and B-type natriuretic peptide prohormones.

(b) Another preferred type of method uses a labelled first binding substance. In such methods, the complex of labelled first binding substance and peptides derived from both A- and B-type natriuretic peptide prohormones is assayed giving a proportionally cumulative measure of the amount of peptides derived from both A-

and B-type natriuretic peptide prohormones in the sample. A specific case is the one where the first binding substance can be the natriuretic receptor GC-A or a fragment or extension thereof, a bi-, oligospecific or bifunctional antibody recognising peptides derived from both A- and B-type natriuretic peptide prohormones and agent.

(c) An additional preferred type of method relies on the use of a labelled antibody to binding substance, which antibody may be produced in a different animal species than the used first or secondary antibody in case of binding substance comprising an antibody.

(d) A further method comprises (i) contacting the sample with an agent and a first binding substance, comprising labelled first binding substance or comprising labelled agent; and (ii) detecting and /or quantitatively determining the binding of the labelled first binding substance to the unlabelled agent or labelled agent to the binding substance that recognises peptides derived from both A- and B-type natriuretic peptide prohormones and agent.

(e) A preferred method comprises contacting a sample, which sample is known or suspected to contain peptides derived from both A- and B-type natriuretic peptide prohormones with (in any order): (i) a first binding substance which recognises both peptides derived from both A- and B-type natriuretic peptide prohormones and an agent of the invention; and (ii) a known amount of the labelled agent, which acts as an antigen, such that the label is bound to the binding substance in an amount which depends on the amount of unlabelled peptides derived from both A- and B-type natriuretic peptide prohormones present in the sample; and assaying the amount of the bound and/or unbound label as a proportionally cumulative measure of unlabelled level of peptides derived from both A- and B-type natriuretic peptide prohormones in the sample.

(f) A conventional immunoassay method (e.g. radioimmunoassay) may comprise:

(i) immobilising on a solid support unlabelled first binding substance recognising and binding peptides derived from both A- and B-type natriuretic peptide prohormones and agent of the invention;

(ii) adding a sample containing or suspected of containing the target native peptides derived from both A- and B-type natriuretic peptide prohormones together

with a fixed amount of labelled agent, such that the peptides derived from both A- and B-type natriuretic peptide prohormones and the labelled agent are free to compete for binding to the immobilised binding substance;

5 (iii) separating out the immobilised (bound) material from the non-immobilised (unbound) material;

(iv) determining the amount of binding substance-bound labelled agent; and

(v) comparing the amounts of bound or unbound labelled agent in assay mixtures of test samples with the signal obtained using calibrators with known concentration of agent in order to determine the proportionally cumulative concentration of peptides derived from both A- and B-type natriuretic peptide
10 prohormones in the sample being assayed.

(g). Alternatively, method (f) can be performed in solution, wherein, a second binding substance can be used to either precipitate or otherwise immobilise and separate the first binding substance-antigen complexes. A typical example of this
15 comprises:

(i) contacting a sample containing or suspected of containing the peptides derived from A- and B-type natriuretic peptide prohormones to be detected with a first binding substance recognising peptides derived from both A- and B-type natriuretic peptide prohormones or binding thereto according to the invention in the
20 presence of a fixed amount of a labelled agent of the invention;

(ii) contacting the resulting mixture with an immobilised secondary binding substance which binds to the first binding substance;

(iii) separating out the immobilised material from the non-immobilised material; and

25 (iv) comparing amounts of the labelled agent in the immobilised or non-immobilised material with the amounts obtained using calibrators with known concentration of novel agent to determine the proportionally cumulative concentration of peptides derived from both A- and B-type natriuretic peptide prohormones in the sample being assayed.

30 (h) An immunometric assay employing the use of immobilised unlabelled agent is also envisioned, a typical example of which comprises:

(i) immobilising on a solid support unlabelled agent of the invention;

(ii) adding a sample containing or suspected of containing the target peptides derived from A- and B-type natriuretic peptide prohormones together with a fixed amount of labelled binding substance which recognises peptides derived from both A- and B-type natriuretic peptide prohormones according to the invention, in such a way that peptides derived from both A- and B-type natriuretic peptide prohormones in the sample are free to compete with the immobilised agent of the invention for the labelled binding substance.

(iii) separating out the labelled first binding substance recognising peptides derived from both A- and B-type natriuretic peptide prohormones that is not bound to the immobilised agent of the invention;

(iv) determining the amount of labelled binding substance bound to the immobilised agent of the invention; and

(v) comparing the amounts of immobilised or non-immobilised labelled binding substance in the assay mixtures of test samples with the activity obtained using calibrators with known concentration of agent of the invention, in order to determine the proportionally cumulative concentration of peptides derived from both A- and B-type natriuretic peptide prohormones in the sample being assayed.

Thus the invention provides methods for determination of the proportionally cumulative concentration of peptides derived from both A- and B-type natriuretic peptide prohormones in a sample, showing either an activation or inactivation of both the ANP and BNP systems.

The first binding substance

According to the present method, peptides derived from both proANP and proBNP may be assayed at the same time in a given sample. As above peptides derived from proANP and proBNP include NT-proANP, ANP, NT-proBNP, BNP as well as proANP and proBNP. A sample may comprise other peptides also derived from the prohormones eg by proteolysis. For example, other peptides may include proANP₁₋₃₀, proANP₃₁₋₆₇ or proANP₇₉₋₉₈. Thus in one embodiment, any combination of proANP, NT-proANP, ANP, proBNP, NT-proBNP and BNP, and optionally other derived peptides, may be assayed in the method.

The present assays use a first binding substance which recognises or binds to peptides derived from both A- and B-type natriuretic peptide prohormones, such as

those peptides described above. Thus the substance is able to bind to both proANP and proBNP or to variants, including fragments of both prohormones. In one embodiment the first binding substance may not bind both sets of peptides with equal affinity. Preferably the binding substance binds to naturally occurring proANP, ANP or NT-proANP and/or to naturally occurring proBNP, BNP, or NT-proBNP. For example it may bind to SEQ ID Nos 1, 2 or 3 and SEQ ID Nos 4, 5 or 6, or to allelic variants or species homologues thereof. Alternatively or additionally, the substance may bind to one or more fragments of any of the above sequences, for example fragments which include an epitope, antigenic fragment, or a binding site. Such fragments are discussed in more detail herein.

In one aspect the first binding substance is able to bind to both:

- (a) (i) proANP (SEQ ID NO. 1), ANP (SEQ ID NO. 2) or NT-proANP (SEQ ID NO. 3);
 - (ii) a homologous variant of (i); or
 - (iii) a fragment of (i) or (ii);
- and
- (b) (i) pro-BNP (SEQ ID NO. 4), BNP (SEQ ID NO. 5) or NT-proBNP (SEQ ID NO. 6);
 - (ii) a homologous variant of (i); or
 - (iii) a fragment of (i) or (ii).

Variants and fragments are as defined herein.

Preferably, the homologous variant (ii) has at least 70% identity to (i), and/or the fragment (iii) is at least 6 amino acids in length. It is particularly preferred that the homologous variant (ii) is a species homologue or an allelic variant of (i).

In a preferred embodiment a binding substance according to the invention is able to bind to a peptide comprising or consisting of amino acids 7 to 23 of ANP and/or amino acids 10 to 26 of BNP or variants thereof. These peptide regions form a conserved ring structure in the native molecules.

Preferably a binding substance is able to bind to an epitope of proANP and/or proBNP. For example, suitable epitopes include amino acids 5-13, 1-10, 15-25 and 27-32 of BNP and amino acids 65-76 and 1-13 of NT-proBNP or variants thereof.

In one particularly preferred embodiment, a binding substance is able to bind to one or more peptides selected from proBNP₁₋₃₇, proBNP₁₅₋₂₄, proBNP₁₀₋₂₉, proANP₂₉₋₉₈, proANP₈₂₋₉₆ and proANP₂₀₋₈₀ or variants thereof. For example, a binding substance may be able to bind to both proBNP₁₅₋₂₄ and proANP₈₂₋₉₆ or to both proBNP₁₋₃₇ and proANP₂₉₋₉₈, or to both proBNP₁₀₋₂₉ and proANP₂₀₋₈₀. For example, a binding substance according to the invention may bind to NT-proXNP1 (SEQ ID NO:13), NT-proXNP2 (SEQ ID NO:14), NT-proXNP3 (SEQ ID NO:15) or NT-proXNP4 (SEQ ID NO:17).

In those embodiments of the present invention which use a binding agent of the invention, the first binding substance is also able to bind to the binding agent.

Suitable binding assays for determining binding are known in the art. In general a first binding substance is able to bind a given peptide to an extent that it can be used in a binding and detection assay such as those described herein. For example, a suitable binding substance may bind with at least 50, 60, 70, 80, 90, 95 or 100% of the binding affinity of a specific antibody to the peptide, or of the natriuretic receptor GC-A to the peptide, e.g. of receptor GC-A to ANP or BNP.

The first binding substance as used herein may be a single substance or a mixture of substances. A suitable binding substance may be for example, a receptor or antibody, or fragments or derivatives thereof, with bi- or oligo-specific properties, or a mixture thereof.

Preferably a mixture of binding substances is used as a first binding substance in embodiments where an agent of the invention is also used. A mixture may comprise monospecific, bispecific and/or oligospecific binding substances. Any suitable composition of binding substances may be used that allows detection of proANP- and proBNP-derived peptides according to the present methods. pro-ANP-derived peptide specific binding substances and proBNP-derived peptide specific binding substances may be present in any suitable proportions. For example they may be present in equal amounts or binding capacities. Alternatively, each may be present at, for example, 2x, 3x, 4x, 5x up to 10x the amount or binding capacity of the other. In one preferred embodiment, a 1:1 mixture of proANP-derived peptide-specific binding substance eg antibody and proBNP-derived peptide specific binding substance eg antibody may be used in an assay.

In embodiments where the assay does not include agent of the invention it is preferred that the first binding substance is a single bi- or oligo-specific binding substance. Thus the preferred first binding substance for use in such embodiments is a single substance that is bi- or oligo-functional in binding. That single substance has the binding specificity of the first binding substance as set out above. It may for example, have two or more ligand binding sites, or two or more ligands may bind to one site in the substance with the same or different affinities. For example such a substance may comprise a receptor or antibody or fragments of either.

(a) *Receptors*

An example of a suitable receptor is natriuretic receptor GC-A. A sequence of human GC-A may be found under accession no. P16066 (SEQ ID NO:27). The receptor or a fragment, extension or derivative thereof can be produced by methods known to those skilled in the art (Misono *et al.*, 1999). Briefly, the extracellular ligand binding domain of the receptor (SEQ ID NO:28) may be produced by cloning the DNA sequence encoding the amino acid sequence required for binding both human ANP and BNP, into a suitable prokaryotic or eukaryotic expression vector, transfecting the vector into an appropriate host cell, growing the host cell in a suitable culture medium, and harvesting the recombinant protein. The receptor-derived sequence may be released by enzyme digestion, purified with affinity chromatography and reverse-phase HPLC and identified by peptide mapping and sequencing.

The GC-B receptor (accession no. P20594, SEQ ID NO:29) or ANPrecC or clearance receptor (accession no. P17342, SEQ ID NO:30) may also act as a binding substance.

Thus in one embodiment the first binding substance may comprise:

- (a) natriuretic receptor GC-A (SEQ ID NO: 27), GC-B (SEQ ID NO: 29) or GC-C (SEQ ID NO: 30);
- (b) a homologous variant of (a); or
- (c) a fragment of (a) or (b).

In a preferred embodiment the first binding substance comprises an extracellular binding domain of the natriuretic receptor GC-A (SEQ ID NO: 28) or a homologous variant of fragment thereof.

An extension or derivative of any of the above binding substances may be used. Thus the structure of the molecule may be modified, for example by adding a handle to facilitate attachment to a solid support, while still retaining the binding ability or properties of the molecule.

5 (b) *Antibodies*

The first binding substance may comprise an antibody or a fragment or derivative of an antibody. Thus in one aspect the present invention relates to antibody with the binding specificity set out above.

10 Antibodies may be raised against specific epitopes of the given peptide sequences. An antibody, or other compound, "specifically binds" to a polypeptide when it binds with preferential or high affinity to the protein or proteins for which it is specific but does substantially not bind or binds with only low affinity to other polypeptides. A variety of protocols for competitive binding or immunoradiometric assays to determine the specific binding capability of an antibody are well known in
15 the art (see for example Maddox *et al*, J. Exp. Med. 158, 1211-1226, 1993). Such immunoassays typically involve the formation of complexes between specific protein and antibody and the measurement of complex formation.

An antibody according to the invention may comprise either a whole antibody or a fragment thereof and has the binding specificity set out above. Fragments
20 include Fv, F(ab') and F(ab')₂ fragments, as well as single chain antibodies. A whole antibody is typically an antibody which is produced by any of the methods of producing an antibody which are discussed herein. Typically the antibody is a mammalian antibody, such as a primate, human, rodent (e.g. mouse or rat), rabbit, ovine, porcine, equine or camel antibody. The antibody can be any class or isotype of
25 antibody, for example IgM, but is preferably IgG.

The antibody may be a bispecific antibody which is able to bind to two different antigens, or an oligospecific antibody which is able to bind to more than two different antigens. The antibody may comprise a polyclonal, monoclonal, oligoclonal, bifunctional or crossreacting polyclonal antibody as explained above.

30 A fragment of whole antibody that can be used in the method comprises an antigen binding site, e.g. F(ab') or F(ab)₂ fragments. Such fragments or antibodies may be used to form antibody derivatives. For example the whole antibody or

fragment may be associated with other moieties, such as linkers which may be used to join together two or more fragments or antibodies. Such linkers may be chemical linkers or can be present in the form of a fusion protein with the fragment or whole antibody. The linkers may thus be used to join together whole antibodies or
5 fragments which have the same or different binding specificities, e.g. that can bind the same or different polymorphisms. The antibody may be a 'diabody' formed by joining two variable domains back to back. In one embodiment the antibody is a chimeric antibody comprising sequence from different natural antibodies, for example a humanised antibody. Bifunctional antibodies may be made by chemical
10 combination of fragments with desired characteristics.

Antibodies of the invention can be produced by any suitable method. For example, antibodies, fragments or derivatives thereof may be produced by selecting immunogens to raise antibodies, chemically coupling antibodies or antibody
15 fragments, somatic fusion of monoclonal hybridomas/splenocytes or recombinant techniques. Phage display techniques may be used in antibody production.

Means for preparing and characterising antibodies are well known in the art, see for example Harlow and Lane (1988) "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. For example, an antibody may be produced by raising antibody in a host animal against the whole polypeptide
20 or a fragment thereof, for example an antigenic epitope thereof, or "immunogen". The fragment may be any of the fragments mentioned herein (typically at least 6 or at least 10 or 15 amino acids long). An agent of the invention may be used to raise antibody using known techniques.

A method for producing a polyclonal antibody comprises immunising a
25 suitable host animal, for example an experimental animal, with the immunogen and isolating immunoglobulins from the animal's serum. The animal may therefore be inoculated with the immunogen, blood subsequently removed from the animal and the IgG fraction purified.

Polyclonal and monoclonal antibodies are produced by immunising a suitable
30 host animal (e.g. rabbit, sheep, goat, swine, chicken, guinea pig, rat or mouse) with an immunogen. For example, the immunogen may comprise an agent according to the present invention. Methods of producing polyclonal or monoclonal antibodies are

well-known for those skilled in the art and any of these methods may be used to prepare antibodies. If desired, the immunogen may be administered as a conjugate, in which the immunogen is coupled, for example via a side chain of the amino acid residues to a suitable carrier. The carrier molecule is typically a physiologically acceptable carrier.

After the experimental animal has produced polyclonal antibodies the serum may be used diluted or the desired immunoglobulins may be isolated from the serum. The obtained antibody may be isolated and, if desired, purified, for example to a purity of 70 % - 100%. Typically the animal is inoculated with immunogen, the blood is removed and the IgG fraction is purified.

The methods for producing monoclonal antibodies are also well-known for those skilled in the art (Köhler & Millstein 1975 Nature 256, 495-497). Such methods generally comprise immortalising cells which produce the claimed antibody. Hybridoma cells producing monoclonal antibodies, are produced by fusing spleen cells from an immunised animal with tumour cells. The resulting hybridoma cells are immortalised and the cells produce the desired antibody. The immortalised cell producing the desired antibody may be selected by a conventional procedure. The hybridomas may be grown in culture or injected intraperitoneally, for formation of ascites fluid, or into the bloodstream of an allogeneic or immunocompromised host.

Human antibodies may be produced by *in vitro* immunisation of human lymphocytes, followed by transformation of the lymphocytes with Epstein-Barr virus. Monoclonal antibodies may also be produced by recombinant DNA technology as described by Skerra and Plückthun (1988). It is also possible to use any derivatives, as for example F(ab'), and F(ab')₂ fragments of both monoclonal and polyclonal antibodies prepared by proteolytic reaction of papain and pepsin, respectively, on substantially intact antibodies by methods well known for a person skilled in the art.

Thus the antibodies provided by the invention (and those which are used in the method of the invention) may be made by culturing a cell that expresses the antibody and optionally purifying the antibody from the cell.

The cell used in the process may be one which is obtainable by administering a peptide comprising any of the relevant antigenic peptides to a mammal, extracting B cells from the mammal and selecting a cell from these based on the ability to express an antibody which binds the antigens. Optionally the B cells are
5 immortalised after extraction or selection, for example by fusing them with an immortal cell (to form a hybridoma) or by infection with EBV virus.

Cells that express the antibody comprise a polynucleotide that is capable of expressing the antibody, a polynucleotide that encodes the antibody.

Another type of cell which can be used to make the antibody is one which is
10 recombinant for a polynucleotide which expresses the antibody. Such a cell may be prokaryotic or eukaryotic (such as from any of the mammals mentioned herein).

Antibody may be immobilised on a solid support. Typically the solid support is the surface of the container in which the method is being carried out, such as the surface of a microtitre plate. In other embodiments the support may be a sheet (e.g. a
15 nitrocellulose or nylon sheet) or a bead (e.g. Sepharose or latex). Antibody may be present on an ELISA plate or in a dipstick.

Antibodies of the invention are for example useful in purification, isolation or screening methods involving immunoprecipitation techniques.

The invention also includes a dipstick which can be used to carry out the
20 method of the invention. The dipstick comprises a porous material capable of chromatographically transporting a liquid and one or more of the antibodies mentioned herein. When the dipstick is contacted with the sample it draws up liquid from the sample towards a detection region on the dipstick. Peptides in the sample which derive from proANP or proBNP are detected by their binding to the detection
25 region.

In one embodiment the liquid is drawn through a region in the dipstick containing the antibodies of the invention. These antibodies bind to the relevant peptides forming an antibody/peptide complex. This complex is drawn towards the detection region which contains an agent (immobilised on the dipstick) that binds
30 and thus immobilises the complex in the detection region. This agent is typically a specific binding agent (e.g. an antibody) that binds either the antibody or the peptide

of the complex. The antibody/peptide complex is typically detected in the detection region by the use of a label which is attached to the specific antibody.

In another embodiment protein in the sample is labelled before it is drawn up the dipstick. The labelled protein is then drawn up the dipstick (which has been contacted with sample) and is detected by binding the polymorphism specific antibody (which is bound to the detection region).

Typically the label used in the dipstick systems described above is a visually detectable label which becomes visually detectable (i.e. can be seen with the human eye) when enough antibody/protein complex becomes immobilised in the detection region. A suitable label is a gold (or other colloidal metal) particle or a fluorophore (e.g. fluorescein).

The dipstick may comprise a denaturing agent that causes denaturation of the protein which is drawn up the dipstick. In one embodiment the sample is exposed to denaturing conditions (e.g. contacted with a denaturing agent) before it is contacted with the dipstick.

Agents of the invention (proXNP, NT-proXNP, XNP)

(a) Peptide agents

In one embodiment the present test method utilises an agent (proXNP, XNP or NT-proXNP) which comprises amino acid sequence derived or originating from both proANP and proBNP. The agent mimics proANP- and proBNP- derived peptides in the sample to be tested in particular, naturally occurring peptides. The agent for use in the present method is also recognised or bound by the first binding substance to be used in the method. Thus the agent can compete with the peptides in a sample for binding to the first binding substance in the assays of the invention. An agent may also be used as a calibrator or standard in an assay. Thus the agents are particularly useful for quantifying peptides derived from proANP and proBNP in a sample. For example, in the present assay methods, the measure of peptides in a sample may be expressed as a concentration of agent. Furthermore the agent may be used as an immunogen to produce antibody suitable for use as a first binding substance, according to the methods set out above.

The agent may comprise or consist essentially of a peptide, polypeptide or protein. For example, an agent may comprise or consist of a fusion protein. An

agent according to the invention generally comprises sequence characteristic of proANP and sequence characteristic of proBNP. Thus an agent typically includes at least one peptide sequence derived from proANP and at least one peptide sequence derived from proBNP.

5 In particular an agent may comprise both:

- (a) (i) SEQ ID Nos 1, 2 or 3;
- (ii) an homologous variant of (i); or
- (iii) a fragment of (i) or (ii);

and

- 10 (b) (i) SEQ ID Nos 3, 4 or 5;
- (ii) an homologous variant of (i); or
- (iii) a fragment of (i) or (ii).

Preferably the agent comprises both:

- (a) (i) SEQ ID Nos 1, 2 or 3;
- 15 (ii) a homologous sequence having at least 70% identity to (i); or
- (iii) a fragment of (i) or (ii) which is at least 6 amino acids in length;

and

- (b) (i) SEQ ID Nos 4, 5 or 6;
- (ii) a homologous sequence having at least 70% identity to (i); or
- 20 (iii) a fragment of (i) or (ii) which is at least 6 amino acids in length.

In one preferred embodiment an agent comprises amino acids 7 to 23 of ANP and/or amino acids 10 to 26 of BNP, or variants thereof. These peptides form a conserved ring structure in nature ANP and BNP, which may be conserved in the agent. In one embodiment, an agent comprises an epitope of proANP and/or

25 proBNP. For example, suitable epitopes include amino acids 5 to 13, 1 to 10, 15 to 25 or 27 to 32 of BNP and amino acids 65 to 76 or 1 to 13 of NT-proBNP is particularly preferred that an agent includes peptide sequence derived (according to the above) from both NT-proANP and NT-proBNP (such an agent is referred to as NT-proXNP), or from both ANP and BNP (the agent being then referred to as XNP).

30 In a preferred embodiment the agent may comprise peptide sequence selected from one or more of proBNP₁₋₃₇, proBNP₁₅₋₂₄, proBNP₁₀₋₂₉, proANP₂₉₋₉₈, proANP₈₂₋₉₆ and proANP₂₀₋₈₀ or variants thereof. Preferably an agent comprises at least one

proBNP and at least one proANP sequence selected from this list. Particularly preferred combinations are proBNP₁₅₋₂₄ and proANP₈₂₋₉₆, proBNP₁₋₃₇ and proANP₂₉₋₉₈, or proBNP₁₀₋₂₉ and proANP₂₀₋₈₀. Thus an agent according to the invention may comprise or consist of NT-proXNP1 (SEQ ID NO:13), NT-proXNP2 (SEQ ID NO:14), NT-proXNP3 (SEQ ID NO:15) or NT-proXNP4 (SEQ ID NO:17).

In addition to the peptide sequences derived from proANP and proBNP the agent may include linker or connector amino acid sequence of variable length or composition. Suitable linkers are known in the art. Preferably the structure of the linker is such as to allow attachment of one or more labels (eg fluorescent groups or enzymes) to the linker. For example, one such suitable spacer sequence is Gly-Lys-Tyr-Gly (GKYG) (SEQ ID NO: 16). The Tyr residue permits radioiodination and the Lys residue allows attachment of labels requiring an amino group.

An agent may be immobilised on a solid support, such as those described for antibodies.

An agent of the invention may comprise chemically modified amino acid sequence, e.g. post-translationally modified. For example, it may be glycosylated or comprise modified amino acid residues. It may be modified by the addition of histidine residues to assist purification. It may be desirable to produce peptide or protein in a form suitable for attachment to a solid support. Protein or peptide may thus be modified to enhance its binding to a solid support for example by the addition of a cysteine residue.

(b) Polynucleotides encoding agents

The invention also relates to polynucleotides which encode an agent according to the invention or the peptide part of an agent according to the invention. Such polynucleotides comprise sequence which encodes the agent peptides as defined above and/or sequence which is complementary to the coding sequence.

In particular a polynucleotide of the invention may comprise both:

- (a) (i) SEQ ID NOs 7, 8 or 9;
- (ii) a sequence complementary to (i);
- (iii) a sequence which hybridises under stringent conditions to (i) or (ii);
- (iv) a sequence which is degenerate as a result of the genetic code to (i), (ii) or (iii);

(v) a sequence having at least 70% identity to any of the sequences in (i) to (iv); or

(vi) a fragment of any of the sequences in (i) to (v);

and

5 (b) (i) SEQ ID NOs 10, 11 or 12;

(ii) a sequence complementary to (i);

(iii) a sequence which hybridises under stringent conditions to (i) or (ii);

(iv) a sequence which is degenerate as a result of the genetic code to (i), (ii) or (iii);

10 (v) a sequence having at least 70% identity to any of the sequences in (i) to (iv); or

(vi) a fragment of any of the sequences in (i) to (v).

A polynucleotide may also comprise nucleotide sequence encoding linker or spacer amino acid sequence in the agent. A polynucleotide of the invention typically
15 comprises 1000 base pairs or less, for example 500 base pairs or less. A polynucleotide may comprise up to 200, 300, 400, 500, 600, 700, 800 or 900 base pairs. For example, a polynucleotide may comprise up to 50, 100, 150 or 175 nucleotides.

Typically the polynucleotide is DNA. However, the invention may comprise
20 RNA polynucleotides. The polynucleotides may be single or double stranded, and may include within them synthetic or modified nucleotides.

A polynucleotide of the invention can hybridize to the coding sequence or the complement of the coding sequence of the specified sequence (any of SEQ ID NOs: 7-12) at a level significantly above background. Background hybridization may
25 occur, for example, because of other DNAs present in a DNA library. The signal level generated by the interaction between a polynucleotide of the invention and the coding sequence or complement of the coding sequence of the specific sequence is typically at least 10 fold, preferably at least 100 fold, as intense as interactions between other polynucleotides and the coding sequence of the specific sequence.
30 The intensity of interaction may be measured, for example, by radiolabelling the probe, e.g. with ^{32}P . Selective hybridisation may typically be achieved using conditions of medium to high stringency. However, such hybridisation may be

carried out under any suitable conditions known in the art (see Sambrook *et al*, 1989) For example, if high stringency is required suitable conditions include from 0.1 to 0.2 x SSC at 60 °C up to 65 °C. If lower stringency is required suitable conditions include 2 x SSC at 60 °C.

5 The coding sequence of any of SEQ ID NOs: 7-12 may be modified by nucleotide substitutions, for example from 1, 2 or 3 to 10, 25 or 50 substitutions. The polynucleotide of any of SEQ ID NOs: 7-12 may alternatively or additionally be modified by one or more insertions and/or deletions and/or by an extension at either or both ends. Additional sequences such as signal sequences may also be included.
10 Degenerate substitutions may be made and/or substitutions may be made which would result in a conservative amino acid substitution when the modified sequence is translated, for example as shown in the Table included in the *Variants* section above.

 A nucleotide sequence which is capable of selectively hybridizing to the
15 complement of the DNA coding sequence of any of SEQ ID NOs: 7-12 will generally have at least 70%, at least 80%, at least 90%, at least 95%, at least 98% or at least 99% sequence identity to the specific coding sequence over a region of at least 20, preferably at least 30, for instance at least 40, at least 60, 80, 100 for instance 100 or 200 or more nucleotides or most preferably over the full length of the
20 specific coding sequence

 For example the UWGCG Package provides the BESTFIT program which can be used to calculate homology (for example used on its default settings) (Devereux *et al* (1984) *Nucleic Acids Research* 12, p387-395). The PILEUP and BLAST algorithms can be used to calculate homology or line up sequences (typically
25 on their default settings), for example as described in Altschul (1993) *J. Mol. Evol.* 36:290-300; Altschul *et al* (1990) *J. Mol. Biol.* 215:403-10.

 Software for performing BLAST analyses is publicly available through the National Centre for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pair (HSPs) by identifying
30 short words of length W in the query sequence that either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighbourhood word score threshold

(Altschul *et al*, 1990). These initial neighbourhood word hits act as seeds for initiating searches to find HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Extensions for the word hits in each direction are halted when: the
 5 cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a word length (W) of 11, the
 10 BLOSUM62 scoring matrix (see Henikoff and Henikoff (1992) *Proc. Natl. Acad. Sci. USA* 89: 10915-10919) alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

The BLAST algorithm performs a statistical analysis of the similarity between two sequences; see e.g., Karlin and Altschul (1993) *Proc. Natl. Acad. Sci.*
 15 *USA* 90: 5873-5877. One measure of similarity provided by the BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a sequence is considered similar to another sequence if the smallest sum probability in comparison of the first sequence to the second sequence
 20 is less than about 1, preferably less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

Any combination of the above mentioned degrees of sequence identity and minimum sizes may be used to define polynucleotides of the invention, with the more stringent combinations (i.e. higher sequence identity over longer lengths) being
 25 preferred. Thus, for example a polynucleotide which has at least 90% sequence identity over 25, preferably over 30 nucleotides forms one aspect of the invention, as does a polynucleotide which has at least 95% sequence identity over 40 nucleotides.

Fragments of polynucleotides may be for example, up to 40, or up to 30 nucleotides in length. Preferably the length is up to 5, 10, 15, 20 or 25 nucleotides.

30 In one embodiment, a polynucleotide encoding an agent of the invention may comprise any of SEQ ID NOS: 18 to 21. These sequences encode NT-proXNP1,

NT-proXNP2, NT-proXNP3 and NT-proXNP4 respectively. A polynucleotide may comprise:

- (a) SEQ ID NO 18, 19, 20 or 21;
- (b) a sequence complementary to (a);
- 5 (c) a sequence which hybridises under stringent conditions to (a) or (b);
- (d) a sequence which is degenerate as a result of the genetic code to (a), (b) or (c);
- (e) a sequence having at least 70% identity to any of the sequences in (a) to (d); or
- 10 (f) a fragment of any of the sequences in (a) to (e).

Polynucleotides according to the invention may be produced recombinantly, synthetically, or by any means available to those of skill in the art. They may also be cloned by standard techniques. The polynucleotides are typically provided in isolated and/or purified form.

15 In general, primers will be produced by synthetic means, involving a step wise manufacture of the desired nucleic acid sequence one nucleotide at a time. Techniques for accomplishing this using automated techniques are readily available in the art.

20 Although in general the techniques mentioned herein are well known in the art, reference may be made in particular to Sambrook *et al*, Molecular Cloning: A Laboratory Manual, 1989.

The polynucleotides according to the invention have utility in production of the polypeptide agents according to the invention, which may take place *in vitro*, *in vivo* or *ex vivo*. The polynucleotides may be used in recombinant protein synthesis.

25 Recombinant protein expression methods are known in the art and are discussed further below.

Polynucleotides or primers of the invention may carry a revealing label. Suitable labels include radioisotopes such as ¹²⁵I, ³²P or ³⁵S, enzyme labels, or other protein labels such as biotin. Such labels may be added to polynucleotides or primers

30 of the invention and may be detected using techniques known *per se*.

(c) *Vectors, host cells and expression of peptide agents*

The polynucleotides of the invention may be incorporated into a recombinant replicable vector. The vector may be used to replicate the nucleic acid in a compatible host cell. Therefore, polynucleotides of the invention may be made by introducing a polynucleotide of the invention into a replicable vector, introducing the vector into a compatible host cell and growing the host cell under conditions which bring about replication of the vector.

Preferably the vector is an expression vector comprising a nucleic acid sequence that encodes a polypeptide agent of the invention. Such expression vectors are routinely constructed in the art of molecular biology and may, for example, involve the use of plasmid DNA and appropriate initiators, promoters, enhancers and other elements, which may be necessary, and which are positioned in the correct orientation, in order to allow for protein expression. Other suitable vectors would be apparent to persons skilled in the art. By way of further example in this regard we refer to Sambrook *et al.* 1989.

Preferably, a polynucleotide of the invention or for use in the invention in a vector is operably linked to a control sequence which is capable of providing for the expression of the coding sequence by the host cell, i.e. the vector is an expression vector. The term "operably linked" refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. A regulatory sequence, such as a promoter, "operably linked" to a coding sequence is positioned in such a way that expression of the coding sequence is achieved under conditions compatible with the regulatory sequence.

The vectors may be for example, plasmid, virus or phage vectors provided with a origin of replication, optionally a promoter for the expression of the said polynucleotide and optionally a regulator of the promoter. The vectors may contain one or more selectable marker genes, for example an ampicillin resistance gene in the case of a bacterial plasmid or a resistance gene for a fungal vector.

Promoters and other expression regulation signals may be selected to be compatible with the host cell for which expression is designed. For example, yeast promoters include *S. cerevisiae* GAL4 and ADH promoters, *S. pombe* *nmt1* and *adh* promoter. Mammalian promoters include the metallothionein promoter which can be induced in response to heavy metals such as cadmium. Viral promoters such as the

SV40 large T antigen promoter or adenovirus promoters may also be used. All these promoters are readily available in the art.

Mammalian promoters, such as β -actin promoters, may be used. Tissue-specific promoters are especially preferred. Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR), the rous sarcoma virus (RSV) LTR promoter, the SV40 promoter, the human cytomegalovirus (CMV) IE promoter, adenovirus, HSV promoters (such as the HSV IE promoters), or HPV promoters, particularly the HPV upstream regulatory region (URR). Viral promoters are readily available in the art.

Vectors may be used *in vitro*, for example for the production of DNA or RNA or used to transfect or transform a host cell, for example, a mammalian host cell.

Expression vectors may be transformed into a suitable host cell to provide for expression of a polypeptide agent of the invention or a peptide component of agent according to the invention. The host cell, transformed or transfected with an expression vector as described above, is cultivated under conditions to allow for expression of the polypeptide or fragment, and the expression product is recovered. The polypeptide may be isolated and purified using methods known in the art. For example, phage display techniques may be used. Host cells will be chosen to be compatible with the vector and will preferably be bacterial. Host cells may also be cells of a non-human animal, or a plant transformed with a polynucleotide of the invention.

General

Any of the agents, polypeptides, polynucleotides, vectors, cells or antibodies of the invention may be present in substantially isolated form. They may be mixed with carriers or diluents which will not interfere with their intended use and still be regarded as substantially isolated. They may also be in substantially purified form, in which case they will generally comprise at least 90%, e.g. at least 95%, 98% or 99% of the proteins, polynucleotides, cells or dry mass of the preparation.

Any of the agents, or antibodies of the invention may be labelled, generally with a suitable detectable label. For example, suitable labels include radiolabels, enzyme labels (e.g. alkaline phosphatase and peroxidase), chemical labels such as biotin (which may be detected by avidin or streptavidin conjugated to peroxidase),

lanthanides such as europium and fluorescent labels (e.g. fluorescein and rhodamine), and luminescent or chemiluminescent labels (e.g. acridinium ester, luminol), gold (or other colloid metal) a dye or a particle. Enzyme labels may be detected using a chemiluminescence or chromogenic based system.

5 *Diagnostics and Therapeutics*

The present methods are useful for assessing cardiac health in an individual. In particular, the methods may be used to detect and assess cardiac impairment. A particular example of cardiac disease that may be targeted using the present methods is congestive heart failure.

10 Heart failure is a clinical condition characterised by the inability of the heart to generate a cardiac output sufficient to meet the demands of the body resulting in an activation of the ANP and BNP hormonal systems. Activation of the ANP system is initially associated mainly with atrial overload whereas activation of the BNP system is primarily suggestive of ventricular overload. Inactivation of the systems is a result
15 of either the patient's own regulatory systems or the use of therapeutic drugs for treatment of heart failure.

As above, the present methods, by determining the combined levels of peptides derived from proANP and proBNP in a sample relative to a reference peptide level, can be used to determine activation or inactivation of both the ANP and BNP
20 hormonal systems in an individual. Thus, the present methods may be used to assess functioning of the cardiac systems. The methods of the invention are useful for screening and ruling out of, assessment of severity of, assessment of prognosis, follow up of treatment and guidance of treatment of cardiac disease such as heart failure in patients with cardiac pressure or volume overload.

25 For example, the methods may be used for diagnosis of cardiac disease. The methods may be used to screen individuals, to assess the severity of cardiac condition, to assess prognosis or to gauge susceptibility to, for example cardiac failure. The present methods may also be employed as a follow-up to treatment for cardiac disease and to assess, monitor and guide treatment of cardiac disease. By
30 monitoring activation or inactivation of the ANP and BNP systems according to the present methods, it is possible to assess the effects of treatment in patients suffering heart disease, for example pharmacological therapy. Thus the present methods may

be used to assess patient responsiveness to a particular therapy and to improve the treatment which is provided.

The present methods may be used to assess susceptibility to cardiac disease. Individuals may then be advised on lifestyle changes which may be required to decrease the likelihood of developing or decrease the severity of symptoms associated with cardiac disease such as heart failure. Individuals may be treated prophylactically for the same purpose.

Diagnostic kits

The invention also provides a diagnostic kit. The kit is suitable for use in the present methods and is in general useful for diagnosis and assessment of cardiac condition as described above.

The contents of the kit will be suitable for the assay format that the kit is intended for. Typically the kit comprises a first binding substance as defined herein, and optionally means for detecting binding complexes formed by the first binding substance, also as described herein. A kit may additionally comprise an agent according to the invention, the agent being able to bind to the first binding substance in the kit. The first binding substance and/or the agent may be labelled.

In general a kit may comprise other reagents or components for use in the particular assay, such as buffers, precipitators, labelling and/or detection means. Preferably the kit will include instruction means, such as a package insert instructing the user of the kit as to the kit contents and assay format.

Thus, a kit for a competitive assay may comprise:

- (a) a first binding substance;
- (b) labelled XNP;
- (c) XNP standard; and
- (c) precipitators, buffers etc.

A kit for a sandwich assay may comprise:

- (a) first binding substance;
- (b) labelled second binding substance;
- (c) a standard (XNP or proANP originating peptide + proBNP originating peptide);
- (d) other usual materials according to the detection system.

Examples

The following Examples illustrate the invention. Unless indicated otherwise, the methods used are standard biochemistry and molecular biology techniques.

- 5 Examples of suitable general methodology textbooks include Sambrook *et al*, Molecular Cloning, A Laboratory Manual (1989) and Ausubel *et al*, Current Protocols in Molecular Biology (1995) John Wiley and Sons Inc.

Example 1

Expression and purification of recombinant NT-proXNP

- 10 The nucleotides encoding amino acids 1-37 of human NT-proBNP and those encoding amino acids 29-98 of human NT-proANP are amplified by reverse transcription PCR from human atrial RNA using oligonucleotide primers. The 5'-primer for NT-proBNP amplification contains the cleavage site for the restriction enzyme *Bam*HI (5'-GCGGATCCCACCCGCTGGGCAGCCCCG-3' Seq ID NO:22)
- 15 and the 3'-primer for *Xba*I (5'-GCTCTAGAGGATGTCTGCTCCACC-3' SEQ ID NO:23). The 5'-primer for NT-proANP amplification has *Xba*I linker (5'-GCTCTAGAGAAGATGAGGTCGTGC-3' SEQ ID NO:24) and the 3'-primer has *Eco*RI linker (5'-GCGAATTCTCACCGAGGGGCAGTGAGC-3' SEQ ID NO:25). In addition, the NT-proANP amplicon contains an in-frame termination codon
- 20 (TGA) at its 3'-end preceding the *Eco*RI cleavage site. The other version of NT-proBNP amplicon contains an in-frame codon for Tyr at its 5'-terminus following the *Bam*HI linker sequence (5'-GCGGATCCTACCACCCGCTGGGCAG-3' SEQ ID NO:26). The RT-PCR products are purified by agarose electrophoresis, cleaved with *Xba*I and *Bam*HI or *Eco*RI and subcloned end-to-end (NT-proBNP -> NT-proANP)
- 25 into *Bam*HI/*Eco*RI site of pGEX-4T-1 vector (Amersham Pharmacia Biotech, Uppsala, Sweden). The nucleotide sequences and reading frames of the constructs are confirmed by sequencing.

- The expression and affinity purification of the GST-proteins are carried out according to the following procedure. An overnight culture of *E. coli*, transformed
- 30 with a recombinant plasmid, is diluted 1:100 in 2xYTA and grown at 37°C until the OD at 660 nm reaches 0.6. Isopropyl-1-thio-D-galactopyranoside (IPTG) is added to a final concentration of 0.1 mM and the culture is further incubated for 1-2 h. The

bacterial cells are harvested by centrifugation (7000g for 10 min. at +4°C), resuspended in PBS (50 µl/ml of culture) and sonicated. The cell lysate is cleared at 7000g for 15 min. The supernatant is applied to a glutathione agarose column (Sigma, Saint Louis, MO, USA) and washed three times with PBS. The fusion protein is eluted with 10 mM glutathione in 50 mM Tris-HCl, pH 8.0 and stored in aliquots at 20°C. Samples are separated by SDS-PAGE (12% acrylamide). Both prokaryotic or eukaryotic expression vectors can be used. Accordingly, the whole peptide or at least a portion of said peptide or protein may be produced in prokaryotic or eukaryotic cells.

The recombinant peptides are released from fusion partner by treating with thrombin (Amersham Pharmacia Biotech) at room temperature for 1 h (1U /100 µg protein). The peptides are purified by reverse-phase HPLC using a 4.6 x 150 mm Vydac C₄ column. The column is eluted with a linear 40 min gradient from 20-48 % acetonitrile in aqueous trifluoroacetic acid. Elution rate is 1 ml/min and absorbance at 200-280 nm is measured during HPLC to monitor the purity of products.

An example of the HPLC profile of the purified product consisting of (from NH₂ to CO₂H-terminus human proBNP₁₋₃₇, a short spacer and human proANP₂₉₋₉₈, is presented in Figure 1. Two additional amino acids, glycine and serine, originated from GST are left in the N-terminus of the peptide.

Example 2

Chemical synthesis of NT-proXNP

The combination epitope peptide (NT-proXNP1) SGLQEQRNHLGKYGRSALLKSKLRALLTA (SEQ ID NO:13) comprising (from NH₂- to CO₂H-terminus) the sequences human proBNP₁₅₋₂₄, Gly-Lys-Tyr-Gly spacer and human proANP₈₂₋₉₆, is assembled with an ABI 433A Peptide Synthesizer using Fmoc chemistry. The product is cleaved from the HMP resin with 95 % trifluoroacetic acid/2.5 % H₂O, 2.5 % tri-isopropylsilane, precipitated with diethyl ether, dried and desalted on Sephadex G-15 in 30 % acetic acid. The peptide is purified by reverse phase HPLC in an preparative RCM NovaPak-C₁₈ cartridge (2.5 x 10 cm) with a linear gradient of acetonitrile in aqueous 0.1 % trifluoroacetic acid. The purity is ascertained by reverse phase HPLC in elution conditions with different

selectivity. The identity of the peptide is confirmed by amino acid analysis and peptide mapping.

Example 3

5 Immunoassay of NT-proXNP

Binding substance was prepared from goat antibodies obtained by using affinity purified, fusion protein of GST/NT-proANP₂₀₋₈₀ and NT-proBNP₁₀₋₂₉-TBG as immunogen. Alternatively, other peptide antigens (prepared with the methods described in Example 2, containing sequences from both NT-proBNP and NT-proANP) are coupled to bovine thyroglobulin (TBG) or key hole limpet hemocyanin
10 by water soluble carbodiimide, prior to immunisation. A goat is injected at multiple sites at the back with 1.5 mg of immunogen in 1 ml 0.9 % NaCl emulsified in equal volume of Freund's complete adjuvant. Boosters of 0.5 mg in Freund's incomplete adjuvant are given two times at 2-3 weeks intervals and blood is drawn 14 days after
15 the last injections. The antisera are chosen according to the titre of binding the radioiodinated peptide or protein agent of the invention (see below), as well as the sensitivity and specificity with regard to related peptides and peptide or protein agent of the invention. Any modification of the peptide or protein agent of the invention or any fragment or derivative thereof may also be used for immunisation purposes to
20 produce either monoclonal or polyclonal antibodies.

Recombinant NT-proBNP₁₋₃₇/NT-proANP₂₉₋₉₈ (1.5 µg), produced as described in Example 1, is radioiodinated using 0.5 mCi Na¹²⁵I in the presence of 10 µg chloramine-T in 0.5 M phosphate buffer, pH 7.5 for 60 sec., followed by the addition of 10 µg sodium disulphite. The mixture is desalted by Sephadex G-25 gel filtration
25 and purified by reverse phase HPLC in a Symmetry C₁₈ column and a 30 min linear 20 % to 50 % acetonitrile gradient in aqueous trifluoroacetic acid at a flow rate of 1 ml/min. Fractions of 1 ml are collected and monitored for radioactivity in a Multi-Gamma counter (Wallac, Turku, Finland).

Recombinant NT-proBNP₁₋₃₇/NT-proANP₂₉₋₉₈, produced as described in
30 Example 1, is used also as the assay calibrator in the NT-proXNP immunoassay. The assay buffer used for all dilutions consists of 0.04 M sodium hydrogen phosphate, 0.01 M sodium dihydrogen phosphate, 0.1 M NaCl, 0.1 % gelatine, 0.05 % Triton X-

100, pH 7.4). Plasma or serum samples are incubated in duplicates of 25 μ l with 100 μ l of antiserum and 100 μ l of tracer solution (containing approx. 8 000 cpm of iodinated peptide) for 16-24 h at +4°C. Calibration is performed by incubating calibrators (0.08-8 nmol l⁻¹) with the same amount and concentration of antiserum, tracer and anti-antiserum for the same time period as above. The amount of antiserum assayed was determined to bind 40-50% of the tracer when no competitor was present. Bound and free NT-proXNP are separated by precipitation with donkey anti-goat IgG in 0.5 ml of 8 % polyethylene glycol 6000, containing normal goat serum carrier (1 μ l). After centrifugation, the pellet is counted for radioactivity. An example of a reference curve obtained by this type of assay is presented in Figure 2.

The Figure shows a competitive binding curve for immunoassay of NT-proXNP. The assay utilises recombinant NT-proBNP₁₋₃₇/NT-proANP₂₉₋₉₈ as calibrator and tracer and polyclonal goat antibody based binding substance to recognise NT-proXNP, NT-proANP and NT-proBNP simultaneously. The X-axis depicts the amount of calibrator added and the Y-axis Bound/Bound with no calibrator added.

The immunoassay of NT-proXNP described in Example 3 was used to determine the serum levels of NT-proXNP in 700 patients with cardiac disorders. The results are shown in Figure 3. The levels of NT-proXNP are highly significantly correlating with NT-proANP and NT-proBNP levels measured from the same samples by separate in-house radioimmunoassays.

The methods of Example 3 were used to assay the serum levels of NT-proXNP, in 500 cardiac patients classified according to the New York Heart Association (NYHA) scale. The results are shown in Figure 4. The serum levels of NT-proANP and NT-proBNP measured by separate in-house radioimmunoassays from the same samples are displayed for reference as measure of activation ANP and BNP systems.

The methods of Example 3 were used to assay plasma levels of NT-proXNP in patients suffering heart failure and these were correlated with positive effect of pharmacological therapy in the patients. Results are shown in Figure 5. The serum levels of NT-proANP and NT-proBNP measured from the same samples by separate

in-house radioimmunoassays are displayed for reference. Patients (n=11) suffering from heart failure (stable NYHA class II-III) were treated by intravenous infusion of an inodilator for 24 hours. Cardiac output (CO) as ml/min was measured with echocardiography. The levels of NT-proANP, NT-proBNP and NT-proXNP were assayed before and at time point of 24 hours from the start of administration of the drug. The relative sensitivity to detect response to the treatment was determined at the cut-off levels of 10 % increase in CO, as determined with echocardiography and 20 % decrease in NT-ProANP and NT-ProBNP and NT-proXNP as measure of inactivation of ANP and BNP systems. NT-proXNP exceeded cut-off in all of 11 cases, whereas NT-proANP and NT-proBNP and CO excluded cut off in 9 of 11 cases.

REFERENCES

- Altschul *et al.*, J. Mol. Biol. (1990) 215: 403-410
- Altschul *et al.*, J. Mol. Evol. (1993) 36: 290-300
- Ausubel *et al.*, Current Protocols in Molecular Biology (1995) John Wiley & Sons
 5 Inc
- Daly C *et al.*: Natriuretic peptides in the diagnosis of heart disease - First amongst equals? In J Cardiol 2002;84:107-13.
- De Lemos JA *et al.*: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001;345:1014-21.
- 10 Devereux *et al.*, Nucleic Acids Research (1984) 12: 387-395
- Drewett JG, Garbers DL: The family of guanylyl cyclase receptors and their ligands. Endocrine Rev 1994;15:135-62.
- Dzimiri N, Moorji A, Afrane B, Al-Halees Z. Differential regulation of atrial and brain natriuretic peptides and its implications for the management of left
 15 ventricular volume overload. Eur J Clin Invest 2002;32:563-9.
- Harlow and Lane "Antibodies: A Laboratory Manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1988)
- Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA (1992) 89: 10915-10919
- Kannel WB *et al.*: Changing epidemiological features of heart failure. Br Heart J
 20 1994;72:S3-S9
- Karlin and Altschul, Proc. Natl. Acad. Sci. USA (1993) 90: 5873-5877
- Köhler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7.
- McDonagh TA *et al.*: Symptomatic and asymptomatic left-ventricular systolic
 25 dysfunction in an urban population. Lancet 1997;350:829-33.
- Maddox *et al.*, J. Exp. Med. (1993) 158: 1211-1226
- Misono K, Sivasubramanian N, Berkner K, Xhang X. Expression and purification of the extracellular ligand-binding domain of the atrial natriuretic peptide (ANP) receptor: monovalent binding with ANP induces 2:2 complexes. Biochemistry
 30 1999;38:516-23
- Omland T *et al.*: N-terminal pro-B-type natriuretic peptide and long-term mortality in acute in coronary syndromes. Circulation 2002;106:2913-8.

- Remes M, Miettinen H, Reunanen A, Pyörälä K. Validity of clinical diagnosis of heart failure in primary health care. *Eur Heart J* 1991;12:315-21.
- Sagnella GA: Measurement and significance of circulating natriuretic peptides in cardiovascular diseases. *Clin Sci* 1998;95:519-29.
- 5 Sambrook et al. *Molecular Cloning, A Laboratory Manual* (1989)
- Skerra A, Plückthun A: Assembly of a functional immunoglobulin Fv fragment in *Escherichia coli*. *Science* 1988;240:1038-41.
- Talwar S *et al.*: Towards a blood test for heart failure: the potential use of circulating natriuretic peptides. *J Clin Pharmacol* 2000;50:15-20.
- 10 Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Troughton RW *et al.*: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. *Lancet* 2000;355:1126-30.
- Yasue H *et al.*: Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. *Circulation* 1994;90:195-203.
- 15 Yoshimura M *et al.*: Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. *Circulation* 1993;87:464-469.

SEQUENCE LISTING

<110> ORION CORPORATION

<120> ASSAY

<130> P.88837 JHS

<160> 30

<170> PatentIn version 3.0

<210> 1

<211> 126

<212> PRT

<213> Homo sapiens

<400> 1

```

Asn Pro Met Tyr Asn Ala Val Ser Asn Ala Asp Leu Met Asp Phe Lys
1          5          10          15
Asn Leu Leu Asp His Leu Glu Glu Lys Met Pro Leu Glu Asp Glu Val
20          25          30
Val Pro Pro Gln Val Leu Ser Glu Pro Asn Glu Glu Ala Gly Ala Ala
35          40          45
Leu Ser Pro Leu Pro Glu Val Pro Pro Trp Thr Gly Glu Val Ser Pro
50          55          60
Ala Gln Arg Asp Gly Gly Ala Leu Gly Arg Gly Pro Trp Asp Ser Ser
65          70          75          80
Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu Leu Thr Ala
85          90          95
Pro Arg Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg
100         105         110
Ile Gly Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
115         120         125

```

<210> 2

<211> 28

<212> PRT

<213> Homo sapiens

<400> 2

```

Ser Leu Arg Arg Ser Ser Cys Phe Gly Gly Arg Met Asp Arg Ile Gly
1          5          10          15
Ala Gln Ser Gly Leu Gly Cys Asn Ser Phe Arg Tyr
20          25

```

<210> 3

<211> 98

<212> PRT

<213> Homo sapiens

<400> 3

```

Asn Pro Met Tyr Asn Ala Val Ser Asn Ala Asp Leu Met Asp Phe Lys
1          5          10          15

```

Asn Leu Leu Asp His Leu Glu Glu Lys Met Pro Leu Glu Asp Glu Val
 20 25 30
 Val Pro Pro Gln Val Leu Ser Glu Pro Asn Glu Glu Ala Gly Ala Ala
 35 40 45
 Leu Ser Pro Leu Pro Glu Val Pro Pro Trp Thr Gly Glu Val Ser Pro
 50 55 60
 Ala Gln Arg Asp Gly Gly Ala Leu Gly Arg Gly Pro Trp Asp Ser Ser
 65 70 75 80
 Asp Arg Ser Ala Leu Leu Lys Ser Lys Leu Arg Ala Leu Leu Thr Ala
 85 90 95
 Pro Arg

<210> 4
 <211> 108
 <212> PRT
 <213> Homo sapiens

<400> 4

His Pro Leu Gly Ser Pro Gly Ser Ala Ser Asp Leu Glu Thr Ser Gly
 1 5 10 15
 Leu Gln Glu Gln Arg Asn His Leu Gln Gly Lys Leu Ser Glu Leu Gln
 20 25 30
 Val Glu Gln Thr Ser Leu Glu Pro Leu Gln Glu Ser Pro Arg Pro Thr
 35 40 45
 Gly Val Trp Lys Ser Arg Glu Val Ala Thr Glu Gly Ile Arg Gly His
 50 55 60
 Arg Lys Met Val Leu Tyr Thr Leu Arg Ala Pro Arg Ser Pro Lys Met
 65 70 75 80
 Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met Asp Arg Ile Ser Ser
 85 90 95
 Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His
 100 105

<210> 5
 <211> 32
 <212> PRT
 <213> Homo sapiens

<400> 5

Ser Pro Lys Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met Asp
 1 5 10 15
 Arg Ile Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His
 20 25 30

<210> 6
 <211> 76
 <212> PRT
 <213> Homo sapiens

<400> 6

His Pro Leu Gly Ser Pro Gly Ser Ala Ser Asp Leu Glu Thr Ser Gly
 1 5 10 15
 Leu Gln Glu Gln Arg Asn His Leu Gln Gly Lys Leu Ser Glu Leu Gln
 20 25 30

Val Glu Gln Thr Ser Leu Glu Pro Leu Gln Glu Ser Pro Arg Pro Thr
 35 40 45
 Gly Val Trp Lys Ser Arg Glu Val Ala Thr Glu Gly Ile Arg Gly His
 50 55 60

Arg Lys Met Val Leu Tyr Thr Leu Arg Ala Pro Arg
 65 70 75

<210> 7
 <211> 378
 <212> DNA
 <213> Homo sapiens

<400> 7
 aatcccatgt acaatgccgt gtccaacgca gacctgatgg atttcaagaa tttgctggac 60
 catttggaag aaaagatgcc tttagaagat gaggtcgtgc cccacaagt gctcagttag 120
 ccgaatgaag aagcgggggc tgctctcagc cccctccctg aggtgcctcc ctggaccggg 180
 gaagtcagcc cagcccagag agatggaggt gccctcgggc ggggccctg ggactcctct 240
 gatcgatctg cctcctctaaa aagcaagctg agggcgctgc tctactgccc tcggagcctg 300
 cggagatcca gctgcttcgg gggcaggatg gacaggattg gagcccagag cggactgggc 360
 tgtaacagct tccggtac 378

<210> 8
 <211> 84
 <212> DNA
 <213> Homo sapiens

<400> 8
 agcctgcgga gatccagctg cttcgggggc aggatggaca ggattggagc ccagagcgga 60
 ctgggctgta acagcttccg gtac 84

<210> 9
 <211> 294
 <212> DNA
 <213> Homo sapiens

<400> 9
 aatcccatgt acaatgccgt gtccaacgca gacctgatgg atttcaagaa tttgctggac 60
 catttggaag aaaagatgcc tttagaagat gaggtcgtgc cccacaagt gctcagttag 120
 ccgaatgaag aagcgggggc tgctctcagc cccctccctg aggtgcctcc ctggaccggg 180
 gaagtcagcc cagcccagag agatggaggt gccctcgggc ggggccctg ggactcctct 240
 gatcgatctg cctcctctaaa aagcaagctg agggcgctgc tctactgccc tcgg 294

<210> 10
 <211> 324
 <212> DNA
 <213> Homo sapiens

<400> 10
 caccgctgg gcagccccgg ttcagcctcg gacttggaac cgtccggggt acaggagcag 60
 cgcaaccatt tgcagggcaa actgtcggag ctgcaggtgg agcagacatc cctggagccc 120
 ctccaggaga gccccgtcc cacaggtgtc tggaagtccc gggaggtagc caccgagggc 180
 atccgtgggc accgcaaaat ggtcctctac accctgcggg caccacgaag cccaagatg 240
 gtgcaagggt ctggctgctt tgggaggaag atggaccgga tcagctcctc cagtggcctg 300
 ggctgcaaag tgctgaggcg gcat 324

<210> 11
 <211> 96
 <212> DNA

<213> Homo sapiens

<400> 11
 agccccaaga tgggtgcaagg gtctggctgc tttggggagga agatggaccg gatcagctcc 60
 tccagtggcc tgggctgcaa agtgctgagg cggcat 96

<210> 12
 <211> 228
 <212> DNA
 <213> Homo sapiens

<400> 12
 caccgctgg gcagccccgg ttcagcctcg gacttggaaa cgtccggggtt acaggagcag 60
 cgcaaccatt tgcagggcaa actgtcggag ctgcaggtgg agcagacatc cctggagccc 120
 ctccaggaga gccccgtcc cacaggtgtc tggaagtccc gggaggtagc caccgagggc 180
 atccgtgggc accgcaaaat ggtcctctac accctgcggg caccacga 228

<210> 13
 <211> 29
 <212> PRT
 <213> Artificial sequence

<400> 13

Ser	Gly	Leu	Gln	Glu	Gln	Arg	Asn	His	Leu	Gly	Lys	Tyr	Gly	Arg	Ser
1			5						10					15	
Ala	Leu	Leu	Lys	Ser	Lys	Leu	Arg	Ala	Leu	Leu	Thr	Ala			
			20					25							

<210> 14
 <211> 107
 <212> PRT
 <213> Artificial sequence

<400> 14

His	Pro	Leu	Gly	Ser	Pro	Gly	Ser	Ala	Ser	Asp	Leu	Glu	Thr	Ser	Gly
1			5						10					15	
Leu	Gln	Glu	Gln	Arg	Asn	His	Leu	Gln	Gly	Lys	Leu	Ser	Glu	Leu	Gln
			20					25					30		
Val	Glu	Gln	Thr	Ser	Glu	Asp	Glu	Val	Val	Pro	Pro	Gln	Val	Leu	Ser
			35				40					45			
Glu	Pro	Asn	Glu	Glu	Ala	Gly	Ala	Ala	Leu	Ser	Pro	Leu	Pro	Glu	Val
			50			55					60				
Pro	Pro	Trp	Thr	Gly	Glu	Val	Ser	Pro	Ala	Gln	Arg	Asp	Gly	Gly	Ala
65					70				75					80	
Leu	Gly	Arg	Gly	Pro	Trp	Asp	Ser	Ser	Asp	Arg	Ser	Ala	Leu	Leu	Lys
				85				90					95		
Ser	Lys	Leu	Arg	Ala	Leu	Leu	Thr	Ala	Pro	Arg					
			100					105							

<210> 15
 <211> 81
 <212> PRT
 <213> Artificial sequence

<400> 15

```

Ser Asp Leu Glu Thr Ser Gly Leu Gln Glu Gln Arg Asn His Leu Gln
1          5          10          15
Gly Lys Leu Ser Asp His Leu Glu Glu Lys Met Pro Leu Glu Asp Glu
          20          25          30
Val Val Pro Pro Gln Val Leu Ser Glu Pro Asn Glu Glu Ala Gly Ala
          35          40          45
Ala Leu Ser Pro Leu Pro Glu Val Pro Pro Trp Thr Gly Glu Val Ser
          50          55          60
Pro Ala Gln Arg Asp Gly Gly Ala Leu Gly Arg Gly Pro Trp Asp Ser
65          70          75          80
Ser

```

<210> 16
 <211> 4
 <212> PRT
 <213> Artificial sequence

<400> 16

```

Gly Lys Tyr Gly
1

```

<210> 17
 <211> 174
 <212> PRT
 <213> Artificial sequence

<400> 17

```

His Pro Leu Gly Ser Pro Gly Ser Ala Ser Asp Leu Glu Thr Ser Gly
1          5          10          15
Leu Gln Glu Gln Arg Asn His Leu Gln Gly Lys Leu Ser Glu Leu Gln
          20          25          30
Val Glu Gln Thr Ser Leu Glu Pro Leu Gln Glu Ser Pro Arg Pro Thr
          35          40          45
Gly Val Trp Lys Ser Arg Glu Val Ala Thr Glu Gly Ile Arg Gly His
          50          55          60
Arg Lys Met Val Leu Tyr Thr Leu Arg Ala Pro Arg Asn Pro Met Tyr
65          70          75          80
Asn Ala Val Ser Asn Ala Asp Leu Met Asp Phe Lys Asn Leu Leu Asp
          85          90          95
His Leu Glu Glu Lys Met Pro Leu Glu Asp Glu Val Val Pro Pro Gln
          100          105          110
Val Leu Ser Glu Pro Asn Glu Glu Ala Gly Ala Ala Leu Ser Pro Leu
          115          120          125
Pro Glu Val Pro Pro Trp Thr Gly Glu Val Ser Pro Ala Gln Arg Asp
          130          135          140
Gly Gly Ala Leu Gly Arg Gly Pro Trp Asp Ser Ser Asp Arg Ser Ala
145          150          155          160

```

Leu Leu Lys Ser Lys Leu Arg Ala Leu Leu Thr Ala Pro Arg
 165 170

<210> 18
 <211> 75
 <212> DNA
 <213> Artificial sequence

<400> 18
 tccgggttac aggagcagcg caaccatttg cgatctgccc tcctaaaaag caagctgagg 60
 gcgctgctca ctgcc 75

<210> 19
 <211> 321
 <212> DNA
 <213> Artificial sequence

<400> 19
 caccgcgtgg gcagccccgg ttcagcctcg gacttggaag cgtccgggtt acaggagcag 60
 cgcaaccatt tgcagggcaa actgtcggag ctgcagggtg agcagacatc cgaagatgag 120
 gtcgtgcccc cacaagtgtc cagtgcggcg aatgaagaag cgggggctgc tctcagcccc 180
 ctccctgagg tgcctccctg gaccggggaa gtcagcccag cccagagaga tggaggtgcc 240
 ctccggcgagg gccctggga ctccctctgat cgatctgccc tcctaaaaag caagctgagg 300
 gcgctgctca ctgcccctcg g 321

<210> 20
 <211> 241
 <212> DNA
 <213> Artificial sequence

<400> 20
 tcggacttgg aaacgtccgg gttacaggag cagcgcaacc atttgcaggg caaactgtga 60
 ccatttgga gaaaagatgc ctttagaaga tgaggctgtg cccccacaag tgctcagtga 120
 gccgaatgaa gaagcggggg ctgctctcag cccctccct gaggtgcctc cctggaccgg 180
 ggaagtcagc ccagcccaga gagatggagg tgccctcggg cggggcccct gggactcctc 240
 t 241

<210> 21
 <211> 522
 <212> DNA
 <213> Artificial sequence

<400> 21
 caccgcgtgg gcagccccgg ttcagcctcg gacttggaag cgtccgggtt acaggagcag 60
 cgcaaccatt tgcagggcaa actgtcggag ctgcagggtg agcagacatc cctggagccc 120
 ctccaggaga gccccgtcc cacagggtgtc tggaagtccc gggaggtagc caccgagggc 180
 atccgtgggc accgcaaaat ggtcctctac accctgcggg caccacgaaa tcccatgtac 240
 aatgccgtgt ccaacgcaga cctgatggat ttcaagaatt tgctggacca tttggaagaa 300
 aagatgcctt tagaagatga ggtcgtgccc ccacaagtgc tcagtgcagc gaatgaagaa 360
 gcgggggctg ctctcagccc cctccctgag gtgcctccct ggaccgggga agtcagccca 420
 gccagagag atggagggtg cctcggggcg ggcccctggg actcctctga tcgatctgcc 480
 ctccataaaa gcaagctgag ggcgctgctc actgcccctc gg 522

<210> 22
 <211> 27
 <212> DNA
 <213> Artificial sequence

<400> 22
 gcggatccca cccgctgggc agccccg

27

<210> 23
 <211> 24
 <212> DNA
 <213> Artificial sequence

<400> 23
 gctctagagg atgtctgctc cacc

24

<210> 24
 <211> 24
 <212> DNA
 <213> Artificial sequence

<400> 24
 gctctagaga agatgaggtc gtgc

24

<210> 25
 <211> 27
 <212> DNA
 <213> Artificial sequence

<400> 25
 gcgaattctc accgaggggc agtgagc

27

<210> 26
 <211> 25
 <212> DNA
 <213> Artificial sequence

<400> 26
 gcggatccta ccacccgctg ggcag

25

<210> 27
 <211> 1061
 <212> PRT
 <213> Homo sapiens

<400> 27

Met Pro Gly Pro Arg Arg Pro Ala Gly Ser Arg Leu Arg Leu Leu Leu
 1 5 10 15
 Leu Leu Leu Leu Pro Pro Leu Leu Leu Leu Arg Gly Ser His Ala
 20 25 30
 Gly Asn Leu Thr Val Ala Val Val Leu Pro Leu Ala Asn Thr Ser Tyr

35				40				45							
Pro	Trp	Ser	Trp	Ala	Arg	Val	Gly	Pro	Ala	Val	Glu	Leu	Ala	Leu	Ala
50						55					60				
Gln	Val	Lys	Ala	Arg	Pro	Asp	Leu	Leu	Pro	Gly	Trp	Thr	Val	Arg	Thr
65					70					75					80
Val	Leu	Gly	Ser	Ser	Glu	Asn	Ala	Leu	Gly	Val	Cys	Ser	Asp	Thr	Ala
				85					90					95	
Ala	Pro	Leu	Ala	Ala	Val	Asp	Leu	Lys	Trp	Glu	His	Asn	Pro	Ala	Val
				100					105					110	
Phe	Leu	Gly	Pro	Gly	Cys	Val	Tyr	Ala	Ala	Ala	Pro	Val	Gly	Arg	Phe
							120							125	
Thr	Ala	His	Trp	Arg	Val	Pro	Leu	Leu	Thr	Ala	Gly	Ala	Pro	Ala	Leu
	130					135					140				
Gly	Phe	Gly	Val	Lys	Asp	Glu	Tyr	Ala	Leu	Thr	Thr	Arg	Ala	Gly	Pro
145					150					155					160
Ser	Tyr	Ala	Lys	Leu	Gly	Asp	Phe	Val	Ala	Ala	Leu	His	Arg	Arg	Leu
				165					170					175	
Gly	Trp	Glu	Arg	Gln	Ala	Leu	Met	Leu	Tyr	Ala	Tyr	Arg	Pro	Gly	Asp
			180						185					190	
Glu	Glu	His	Cys	Phe	Phe	Leu	Val	Glu	Gly	Leu	Phe	Met	Arg	Val	Arg
		195					200						205		
Asp	Arg	Leu	Asn	Ile	Thr	Val	Asp	His	Leu	Glu	Phe	Ala	Glu	Asp	Asp
	210					215							220		
Leu	Ser	His	Tyr	Thr	Arg	Leu	Leu	Arg	Thr	Met	Pro	Arg	Lys	Gly	Arg
225					230					235					240
Val	Ile	Tyr	Ile	Cys	Ser	Ser	Pro	Asp	Ala	Phe	Arg	Thr	Leu	Met	Leu
				245					250					255	
Leu	Ala	Leu	Glu	Ala	Gly	Leu	Cys	Gly	Glu	Asp	Tyr	Val	Phe	Phe	His
			260						265					270	
Leu	Asp	Ile	Phe	Gly	Gln	Ser	Leu	Gln	Gly	Gly	Gln	Gly	Pro	Ala	Pro
	275						280						285		
Arg	Arg	Pro	Trp	Glu	Arg	Gly	Asp	Gly	Gln	Asp	Val	Ser	Ala	Arg	Gln
	290					295					300				
Ala	Phe	Gln	Ala	Ala	Lys	Ile	Ile	Thr	Tyr	Lys	Asp	Pro	Asp	Asn	Pro
305					310					315					320
Glu	Tyr	Leu	Glu	Phe	Leu	Lys	Gln	Leu	Lys	His	Leu	Ala	Tyr	Glu	Gln
				325					330					335	
Phe	Asn	Phe	Thr	Met	Glu	Asp	Gly	Leu	Val	Asn	Thr	Ile	Pro	Ala	Ser
				340					345					350	
Phe	His	Asp	Gly	Leu	Leu	Leu	Tyr	Ile	Gln	Ala	Val	Thr	Glu	Thr	Leu
		355					360						365		
Ala	His	Gly	Gly	Thr	Val	Thr	Asp	Gly	Glu	Asn	Ile	Thr	Gln	Arg	Met
	370					375					380				
Trp	Asn	Arg	Ser	Phe	Gln	Gly	Val	Thr	Gly	Tyr	Leu	Lys	Ile	Asp	Ser
385					390					395					400
Ser	Gly	Asp	Arg	Glu	Thr	Asp	Phe	Ser	Leu	Trp	Asp	Met	Asp	Pro	Glu
				405					410					415	
Asn	Gly	Ala	Phe	Arg	Val	Val	Leu	Asn	Tyr	Asn	Gly	Thr	Ser	Gln	Glu
				420					425					430	
Leu	Val	Ala	Val	Ser	Gly	Arg	Lys	Leu	Asn	Trp	Pro	Leu	Gly	Tyr	Pro
		435					440						445		
Pro	Pro	Asp	Ile	Pro	Lys	Cys	Gly	Phe	Asp	Asn	Glu	Asp	Pro	Ala	Cys
	450					455					460				
Asn	Gln	Asp	His	Leu	Ser	Thr	Leu	Glu	Val	Leu	Ala	Leu	Val	Gly	Ser
465					470					475					480
Leu	Ser	Leu	Leu	Gly	Ile	Leu	Ile	Val	Ser	Phe	Phe	Ile	Tyr	Arg	Lys
				485					490					495	
Met	Gln	Leu	Glu	Lys	Glu	Leu	Ala	Ser	Glu	Leu	Trp	Arg	Val	Arg	Trp

										500						505						510				
Glu	Asp	Val	Glu	Pro	Ser	Ser	Leu	Glu	Arg	His	Leu	Arg	Ser	Ala	Gly											
																515										
Ser	Arg	Leu	Thr	Leu	Ser	Gly	Arg	Gly	Ser	Asn	Tyr	Gly	Ser	Leu	Leu											
																530										
Thr	Thr	Glu	Gly	Gln	Phe	Gln	Val	Phe	Ala	Lys	Thr	Ala	Tyr	Tyr	Lys											
																545										
Gly	Asn	Leu	Val	Ala	Val	Lys	Arg	Val	Asn	Arg	Lys	Arg	Ile	Glu	Leu											
																565										
Thr	Arg	Lys	Val	Leu	Phe	Glu	Leu	Lys	His	Met	Arg	Asp	Val	Gln	Asn											
																580										
Glu	His	Leu	Thr	Arg	Phe	Val	Gly	Ala	Cys	Thr	Asp	Pro	Pro	Asn	Ile											
																595										
Cys	Ile	Leu	Thr	Glu	Tyr	Cys	Pro	Arg	Gly	Ser	Leu	Gln	Asp	Ile	Leu											
																610										
Glu	Asn	Glu	Ser	Ile	Thr	Leu	Asp	Trp	Met	Phe	Arg	Tyr	Ser	Leu	Thr											
																625										
Asn	Asp	Ile	Val	Lys	Gly	Met	Leu	Phe	Leu	His	Asn	Gly	Ala	Ile	Cys											
																645										
Ser	His	Gly	Asn	Leu	Lys	Ser	Ser	Asn	Cys	Val	Val	Asp	Gly	Arg	Phe											
																660										
Val	Leu	Lys	Ile	Thr	Asp	Tyr	Gly	Leu	Glu	Ser	Phe	Arg	Asp	Leu	Asp											
																675										
																680										
																685										
																690										
Pro	Glu	Gln	Gly	His	Thr	Val	Tyr	Ala	Lys	Lys	Leu	Trp	Thr	Ala	Pro											
																695										
Glu	Leu	Leu	Arg	Met	Ala	Ser	Pro	Pro	Val	Arg	Gly	Ser	Gln	Ala	Gly											
																705										
Asp	Val	Tyr	Ser	Phe	Gly	Ile	Ile	Leu	Gln	Glu	Ile	Ala	Leu	Arg	Ser											
																725										
Gly	Val	Phe	His	Val	Glu	Gly	Leu	Asp	Leu	Ser	Pro	Lys	Glu	Ile	Ile											
																740										
Glu	Arg	Val	Thr	Arg	Gly	Glu	Gln	Pro	Pro	Phe	Arg	Pro	Ser	Leu	Ala											
																755										
Leu	Gln	Ser	His	Leu	Glu	Glu	Leu	Gly	Leu	Leu	Met	Gln	Arg	Cys	Trp											
																770										
Ala	Glu	Asp	Pro	Gln	Glu	Arg	Pro	Pro	Phe	Gln	Gln	Ile	Arg	Leu	Thr											
																785										
Leu	Arg	Lys	Phe	Asn	Arg	Glu	Asn	Ser	Ser	Asn	Ile	Leu	Asp	Asn	Leu											
																805										
Leu	Ser	Arg	Met	Glu	Gln	Tyr	Ala	Asn	Asn	Leu	Glu	Glu	Leu	Val	Glu											
																820										
Glu	Arg	Thr	Gln	Ala	Tyr	Leu	Glu	Glu	Lys	Arg	Lys	Ala	Glu	Ala	Leu											
																835										
Leu	Tyr	Gln	Ile	Leu	Pro	His	Ser	Val	Ala	Glu	Gln	Leu	Lys	Arg	Gly											
																850										
Glu	Thr	Val	Gln	Ala	Glu	Ala	Phe	Asp	Ser	Val	Thr	Ile	Tyr	Phe	Ser											
																865										
Asp	Ile	Val	Gly	Phe	Thr	Ala	Leu	Ser	Ala	Glu	Ser	Thr	Pro	Met	Gln											
																885										
Val	Val	Thr	Leu	Leu	Asn	Asp	Leu	Tyr	Thr	Cys	Phe	Asp	Ala	Val	Ile											
																900										
Asp	Asn	Phe	Asp	Val	Tyr	Lys	Val	Glu	Thr	Ile	Gly	Asp	Ala	Tyr	Met											
																915										
Val	Val	Ser	Gly	Leu	Pro	Val	Arg	Asn	Gly	Arg	Leu	His	Ala	Cys	Glu											
																930										
Val	Ala	Arg	Met	Ala	Leu	Ala	Leu	Leu	Asp	Ala	Val	Arg	Ser	Phe	Arg											
																945										
																950										
																955										
																960										

Ile Arg His Arg Pro Gln Glu Gln Leu Arg Leu Arg Ile Gly Ile His
 965 970 975
 Thr Gly Pro Val Cys Ala Gly Val Val Gly Leu Lys Met Pro Arg Tyr
 980 985 990
 Cys Leu Phe Gly Asp Thr Val Asn Thr Ala Ser Arg Met Glu Ser Asn
 995 1000 1005
 Gly Glu Ala Leu Lys Ile His Leu Ser Ser Glu Thr Lys Ala Val Leu
 1010 1015 1020
 Glu Glu Phe Gly Gly Phe Glu Leu Glu Leu Arg Gly Asp Val Glu Met
 1025 1030 1035 1040
 Lys Gly Lys Gly Lys Val Arg Thr Tyr Trp Leu Leu Gly Glu Arg Gly
 1045 1050 1055
 Ser Ser Thr Arg Gly
 1060

<210> 28
 <211> 430
 <212> PRT
 <213> Homo sapiens

<400> 28

Gly Asn Leu Thr Val Ala Val Val Leu Pro Leu Ala Asn Thr Ser Tyr
 1 5 10 15
 Pro Trp Ser Trp Ala Arg Val Gly Pro Ala Val Glu Leu Ala Leu Ala
 20 25 30
 Gln Val Lys Ala Arg Pro Asp Leu Leu Pro Gly Trp Thr Val Arg Thr
 35 40 45
 Val Leu Gly Ser Ser Glu Asn Ala Leu Gly Val Cys Ser Asp Thr Ala
 50 55 60
 Ala Pro Leu Ala Ala Val Asp Leu Lys Trp Glu His Asn Pro Ala Val
 65 70 75 80
 Phe Leu Gly Pro Gly Cys Val Tyr Ala Ala Ala Pro Val Gly Arg Phe
 85 90 95
 Thr Ala His Trp Arg Val Pro Leu Leu Thr Ala Gly Ala Pro Ala Leu
 100 105 110
 Gly Phe Gly Val Lys Asp Glu Tyr Ala Leu Thr Thr Arg Ala Gly Pro
 115 120 125
 Ser Tyr Ala Lys Leu Gly Asp Phe Val Ala Ala Leu His Arg Arg Leu
 130 135 140
 Gly Trp Glu Arg Gln Ala Leu Met Leu Tyr Ala Tyr Arg Pro Gly Asp
 145 150 155 160
 Glu Glu His Cys Phe Phe Leu Val Glu Gly Leu Phe Met Arg Val Arg
 165 170 175
 Asp Arg Leu Asn Ile Thr Val Asp His Leu Glu Phe Ala Glu Asp Asp
 180 185 190
 Leu Ser His Tyr Thr Arg Leu Leu Arg Thr Met Pro Arg Lys Gly Arg
 195 200 205
 Val Ile Tyr Ile Cys Ser Ser Pro Asp Ala Phe Arg Thr Leu Met Leu
 210 215 220
 Leu Ala Leu Glu Ala Gly Leu Cys Gly Glu Asp Tyr Val Phe Phe His
 225 230 235 240
 Leu Asp Ile Phe Gly Gln Ser Leu Gln Gly Gly Gln Gly Pro Ala Pro
 245 250 255
 Arg Arg Pro Trp Glu Arg Gly Asp Gly Gln Asp Val Ser Ala Arg Gln
 260 265 270
 Ala Phe Gln Ala Ala Lys Ile Ile Thr Tyr Lys Asp Pro Asp Asn Pro
 275 280 285

Glu	Tyr	Leu	Glu	Phe	Leu	Lys	Gln	Leu	Lys	His	Leu	Ala	Tyr	Glu	Gln
290						295					300				
Phe	Asn	Phe	Thr	Met	Glu	Asp	Gly	Leu	Val	Asn	Thr	Ile	Pro	Ala	Ser
305					310					315					320
Phe	His	Asp	Gly	Leu	Leu	Tyr	Ile	Gln	Ala	Val	Thr	Glu	Thr	Leu	
				325				330						335	
Ala	His	Gly	Gly	Thr	Val	Thr	Asp	Gly	Glu	Asn	Ile	Thr	Gln	Arg	Met
			340					345					350		
Trp	Asn	Arg	Ser	Phe	Gln	Gly	Val	Thr	Gly	Tyr	Leu	Lys	Ile	Asp	Ser
		355					360					365			
Ser	Gly	Asp	Arg	Glu	Thr	Asp	Phe	Ser	Leu	Trp	Asp	Met	Asp	Pro	Glu
370						375					380				
Asn	Gly	Ala	Phe	Arg	Val	Val	Leu	Asn	Tyr	Asn	Gly	Thr	Ser	Gln	Glu
385					390					395					400
Leu	Val	Ala	Val	Ser	Gly	Arg	Lys	Leu	Asn	Trp	Pro	Leu	Gly	Tyr	Pro
				405					410					415	
Pro	Pro	Asp	Ile	Pro	Lys	Cys	Gly	Phe	Asp	Asn	Glu	Asp	Pro		
			420					425					430		

<210> 29
 <211> 1047
 <212> PRT
 <213> Homo sapiens

<400> 29

Met	Ala	Leu	Pro	Ser	Leu	Leu	Leu	Leu	Val	Ala	Ala	Leu	Ala	Gly	Gly
1				5					10					15	
Val	Arg	Pro	Pro	Gly	Ala	Arg	Asn	Leu	Thr	Leu	Ala	Val	Val	Leu	Pro
			20					25					30		
Glu	His	Asn	Leu	Ser	Tyr	Ala	Trp	Ala	Trp	Pro	Arg	Val	Gly	Pro	Ala
		35					40				45				
Val	Ala	Leu	Ala	Val	Glu	Ala	Leu	Gly	Arg	Ala	Leu	Pro	Val	Asp	Leu
50						55					60				
Arg	Phe	Val	Ser	Ser	Glu	Leu	Glu	Gly	Ala	Cys	Ser	Glu	Tyr	Leu	Ala
65					70					75					80
Pro	Leu	Ser	Ala	Val	Asp	Leu	Lys	Leu	Tyr	His	Asp	Pro	Asp	Leu	Leu
				85					90					95	
Leu	Gly	Pro	Gly	Cys	Val	Tyr	Pro	Ala	Ala	Ser	Val	Ala	Arg	Phe	Ala
			100					105					110		
Ser	His	Trp	Arg	Leu	Pro	Leu	Leu	Thr	Ala	Gly	Ala	Val	Ala	Ser	Gly
		115					120					125			
Phe	Ser	Ala	Lys	Asn	Asp	His	Tyr	Arg	Thr	Leu	Val	Arg	Thr	Gly	Pro
130						135					140				
Ser	Ala	Pro	Lys	Leu	Gly	Glu	Phe	Val	Val	Thr	Leu	His	Gly	His	Phe
145					150					155					160
Asn	Trp	Thr	Ala	Arg	Ala	Ala	Leu	Leu	Tyr	Leu	Asp	Ala	Arg	Thr	Asp
				165					170					175	
Asp	Arg	Pro	His	Tyr	Phe	Thr	Ile	Glu	Gly	Val	Phe	Glu	Ala	Leu	Gln
			180					185					190		
Gly	Ser	Asn	Leu	Ser	Val	Gln	His	Gln	Val	Tyr	Ala	Arg	Glu	Pro	Gly
		195					200					205			
Gly	Pro	Glu	Gln	Ala	Thr	His	Phe	Ile	Arg	Ala	Asn	Gly	Arg	Ile	Val
		210				215					220				
Tyr	Ile	Cys	Gly	Pro	Leu	Glu	Met	Leu	His	Glu	Ile	Leu	Leu	Gln	Ala
225					230					235					240
Gln	Arg	Glu	Asn	Leu	Thr	Asn	Gly	Asp	Tyr	Val	Phe	Phe	Tyr	Leu	Asp
				245					250					255	

Val	Phe	Gly	Glu	Ser	Leu	Arg	Ala	Gly	Pro	Thr	Arg	Ala	Thr	Gly	Arg
			260					265					270		
Pro	Trp	Gln	Asp	Asn	Arg	Thr	Arg	Glu	Gln	Ala	Gln	Ala	Leu	Arg	Glu
		275					280					285			
Ala	Phe	Gln	Thr	Val	Leu	Val	Ile	Thr	Tyr	Arg	Glu	Pro	Pro	Asn	Pro
		290				295				300					
Glu	Tyr	Gln	Glu	Phe	Gln	Asn	Arg	Leu	Leu	Ile	Arg	Ala	Arg	Glu	Asp
305				310					315						320
Phe	Gly	Val	Glu	Leu	Gly	Pro	Ser	Leu	Met	Asn	Leu	Ile	Ala	Gly	Cys
				325				330						335	
Phe	Tyr	Asp	Gly	Ile	Leu	Leu	Tyr	Ala	Glu	Val	Leu	Asn	Glu	Thr	Ile
			340				345					350			
Gln	Glu	Gly	Gly	Thr	Arg	Glu	Asp	Gly	Leu	Arg	Ile	Val	Glu	Lys	Met
		355					360					365			
Gln	Gly	Arg	Arg	Tyr	His	Gly	Val	Thr	Gly	Leu	Val	Val	Met	Asp	Lys
		370				375					380				
Asn	Asn	Asp	Arg	Glu	Thr	Asp	Phe	Val	Leu	Trp	Ala	Met	Gly	Asp	Leu
385				390					395						400
Asp	Ser	Gly	Asp	Phe	Gln	Pro	Ala	Ala	His	Tyr	Ser	Gly	Ala	Glu	Lys
				405				410						415	
Gln	Ile	Trp	Trp	Thr	Gly	Arg	Pro	Ile	Pro	Trp	Val	Lys	Gly	Ala	Pro
			420					425				430			
Pro	Ser	Asp	Asn	Pro	Pro	Cys	Ala	Phe	Asp	Leu	Asp	Asp	Pro	Ser	Cys
		435					440					445			
Asp	Lys	Thr	Pro	Leu	Ser	Thr	Leu	Ala	Ile	Val	Ala	Leu	Gly	Thr	Gly
	450					455					460				
Ile	Thr	Phe	Ile	Met	Phe	Gly	Val	Ser	Ser	Phe	Leu	Ile	Phe	Arg	Lys
465				470					475						480
Leu	Met	Leu	Glu	Lys	Glu	Leu	Ala	Ser	Met	Leu	Trp	Arg	Ile	Arg	Trp
				485				490						495	
Glu	Glu	Leu	Gln	Phe	Gly	Asn	Ser	Glu	Arg	Tyr	His	Lys	Gly	Ala	Gly
			500					505				510			
Ser	Arg	Leu	Thr	Leu	Ser	Leu	Arg	Gly	Ser	Ser	Tyr	Gly	Ser	Leu	Met
	515						520					525			
Thr	Ala	His	Gly	Lys	Tyr	Gln	Ile	Phe	Ala	Asn	Thr	Gly	His	Phe	Lys
	530					535					540				
Gly	Asn	Val	Val	Ala	Ile	Lys	His	Val	Asn	Lys	Lys	Arg	Ile	Glu	Leu
545				550					555						560
Thr	Arg	Gln	Val	Leu	Phe	Glu	Leu	Lys	His	Met	Arg	Asp	Val	Gln	Phe
				565				570						575	
Asn	His	Leu	Thr	Arg	Phe	Ile	Gly	Ala	Cys	Ile	Asp	Pro	Pro	Asn	Ile
			580				585					590			
Cys	Ile	Val	Thr	Glu	Tyr	Cys	Pro	Arg	Gly	Ser	Leu	Gln	Asp	Ile	Leu
	595						600					605			
Glu	Asn	Asp													

Ser Gly Pro Phe Tyr Leu Glu Gly Leu Asp Leu Ser Pro Lys Glu Ile
 725 730 735
 Val Gln Lys Val Arg Asn Gly Gln Arg Pro Tyr Phe Arg Pro Ser Ile
 740 745 750
 Asp Arg Thr Gln Leu Asn Glu Glu Val Leu Leu Met Glu Arg Cys
 755 760 765
 Trp Ala Gln Asp Pro Ala Glu Arg Pro Asp Phe Gly Gln Ile Lys Gly
 770 775 780
 Phe Ile Arg Arg Phe Asn Lys Glu Gly Gly Thr Ser Ile Leu Asp Asn
 785 790 795 800
 Leu Leu Leu Arg Met Glu Gln Tyr Ala Asn Asn Leu Glu Lys Leu Val
 805 810 815
 Glu Glu Arg Thr Gln Ala Tyr Leu Glu Glu Lys Arg Lys Ala Glu Ala
 820 825 830
 Leu Leu Tyr Gln Ile Leu Pro His Ser Val Ala Glu Gln Leu Lys Arg
 835 840 845
 Gly Glu Thr Val Gln Ala Glu Ala Phe Asp Ser Val Thr Ile Tyr Phe
 850 855 860
 Ser Asp Ile Val Gly Phe Thr Ala Leu Ser Ala Glu Ser Thr Pro Met
 865 870 875 880
 Gln Val Val Thr Leu Leu Asn Asp Leu Tyr Thr Cys Phe Asp Ala Ile
 885 890 895
 Ile Asp Asn Phe Asp Val Tyr Lys Val Glu Thr Ile Gly Asp Ala Tyr
 900 905 910
 Met Val Val Ser Gly Leu Pro Gly Arg Asn Gly Gln Arg His Ala Pro
 915 920 925
 Glu Ile Ala Arg Met Ala Leu Ala Leu Leu Asp Ala Val Ser Ser Phe
 930 935 940
 Arg Ile Arg His Arg Pro His Asp Gln Leu Arg Leu Arg Ile Gly Val
 945 950 955 960
 His Thr Gly Pro Val Cys Ala Gly Val Val Gly Leu Lys Met Pro Arg
 965 970 975
 Tyr Cys Leu Phe Gly Asp Thr Val Asn Thr Ala Ser Arg Met Glu Ser
 980 985 990
 Asn Gly Gln Ala Leu Lys Ile His Val Ser Ser Thr Thr Lys Asp Ala
 995 1000 1005
 Leu Asp Glu Leu Gly Cys Phe Gln Leu Glu Leu Arg Gly Asp Val Glu
 1010 1015 1020
 Met Lys Gly Lys Gly Lys Met Arg Thr Tyr Trp Leu Leu Gly Glu Arg
 1025 1030 1035 1040
 Lys Gly Pro Pro Gly Leu Leu
 1045

<210> 30
 <211> 541
 <212> PRT
 <213> homo sapiens

<400> 30

Met Pro Ser Leu Leu Val Leu Thr Phe Ser Pro Cys Val Leu Leu Gly
 1 5 10 15
 Trp Ala Leu Leu Ala Gly Gly Thr Gly Gly Gly Val Gly Gly Gly
 20 25 30
 Gly Gly Gly Ala Gly Ile Gly Gly Gly Arg Gln Glu Arg Glu Ala Leu
 35 40 45
 Pro Pro Gln Lys Ile Glu Val Leu Val Leu Leu Pro Gln Asp Asp Ser
 50 55 60

Tyr	Leu	Phe	Ser	Leu	Thr	Arg	Val	Arg	Pro	Ala	Ile	Glu	Tyr	Ala	Leu
65					70					75					80
Arg	Ser	Val	Glu	Gly	Asn	Gly	Thr	Gly	Arg	Arg	Leu	Leu	Pro	Pro	Gly
				85					90					95	
Thr	Arg	Phe	Gln	Val	Ala	Tyr	Glu	Asp	Ser	Asp	Cys	Gly	Asn	Arg	Ala
			100					105					110		
Leu	Phe	Ser	Leu	Val	Asp	Arg	Val	Ala	Ala	Ala	Arg	Gly	Ala	Lys	Pro
		115					120					125			
Asp	Leu	Ile	Leu	Gly	Pro	Val	Cys	Glu	Tyr	Ala	Ala	Ala	Pro	Val	Ala
		130				135					140				
Arg	Leu	Ala	Ser	His	Trp	Asp	Leu	Pro	Met	Leu	Ser	Ala	Gly	Ala	Leu
145					150					155					160
Ala	Ala	Gly	Phe	Gln	His	Lys	Asp	Ser	Glu	Tyr	Ser	His	Leu	Thr	Arg
				165					170					175	
Val	Ala	Pro	Ala	Tyr	Ala	Lys	Met	Gly	Glu	Met	Met	Leu	Ala	Leu	Phe
			180					185					190		
Arg	His	His	His	Trp	Ser	Arg	Ala	Ala	Leu	Val	Tyr	Ser	Asp	Asp	Lys
		195					200					205			
Leu	Glu	Arg	Asn	Cys	Tyr	Phe	Thr	Leu	Glu	Gly	Val	His	Glu	Val	Phe
	210					215					220				
Gln	Glu	Glu	Gly	Leu	His	Thr	Ser	Ile	Tyr	Ser	Phe	Asp	Glu	Thr	Lys
225					230					235					240
Asp	Leu	Asp	Leu	Glu	Asp	Ile	Val	Arg	Asn	Ile	Gln	Ala	Ser	Glu	Arg
				245					250					255	
Val	Val	Ile	Met	Cys	Ala	Ser	Ser	Asp	Thr	Ile	Arg	Ser	Ile	Met	Leu
			260					265					270		
Val	Ala	His	Arg	His	Gly	Met	Thr	Ser	Gly	Asp	Tyr	Ala	Phe	Phe	Asn
		275					280					285			
Ile	Glu	Leu	Phe	Asn	Ser	Ser	Ser	Tyr	Gly	Asp	Gly	Ser	Trp	Lys	Arg
	290				295						300				
Gly	Asp	Lys	His	Asp	Phe	Glu	Ala	Lys	Gln	Ala	Tyr	Ser	Ser	Leu	Gln
305					310					315					320
Thr	Val	Thr	Leu	Leu	Arg	Thr	Val	Lys	Pro	Glu	Phe	Glu	Lys	Phe	Ser
				325					330					335	
Met	Glu	Val	Lys	Ser	Ser	Val	Glu	Lys	Gln	Gly	Leu	Asn	Met	Glu	Asp
			340					345					350		
Tyr	Val	Asn	Met	Phe	Val	Glu	Gly	Phe	His	Asp	Ala	Ile	Leu	Leu	Tyr
		355					360					365			
Val	Leu	Ala	Leu	His	Glu	Val	Leu	Arg	Ala	Gly	Tyr	Ser	Lys	Lys	Asp
		370				375					380				
Gly	Gly	Lys	Ile	Ile	Gln	Gln	Thr	Trp	Asn	Arg	Thr	Phe	Glu	Gly	Ile
385					390					395					400
Ala	Gly	Gln	Val	Ser	Ile	Asp	Ala	Asn	Gly	Asp	Arg	Tyr	Gly	Asp	Phe
				405					410					415	
Ser	Val	Ile	Ala	Met	Thr	Asp	Val	Glu	Ala	Gly	Thr	Gln	Glu	Val	Ile
			420					425					430		
Gly	Asp	Tyr	Phe	Gly	Lys	Glu	Gly	Arg	Phe	Glu	Met	Arg	Pro	Asn	Val
		435					440					445			
Lys	Tyr	Pro	Trp	Gly	Pro	Leu	Lys	Leu	Arg	Ile	Asp	Glu	Asn	Arg	Ile
	450					455					460				
Val	Glu	His	Thr	Asn	Ser	Ser	Pro	Cys	Lys	Ser	Ser	Gly	Gly	Leu	Glu
465					470					475					480
Glu	Ser	Ala	Val	Thr	Gly	Ile	Val	Val	Gly	Ala	Leu	Leu	Gly	Ala	Gly
				485					490					495	
Leu	Leu	Met	Ala	Phe	Tyr	Phe	Phe	Arg	Lys	Lys	Tyr	Arg	Ile	Thr	Ile
			500					505					510		
Glu	Arg	Arg	Thr	Gln	Gln	Glu	Glu	Ser	Asn	Leu	Gly	Lys	His	Arg	Glu
			515				520					525			

Leu Arg Glu Asp Ser Ile Arg Ser His Phe Ser Val Ala
530 535 540

CLAIMS

1. An *in vitro* method of determining activation or inactivation of the atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems, the method comprising detecting the presence or amount of atrial and brain natriuretic peptide prohormones (proANP and proBNP) or fragments thereof in a sample.

2. A method according to claim 1, which comprises contacting the sample with a bi- or oligo- specific first binding substance that is able to bind to both:

- 10 (a) (i) proANP (SEQ ID NO. 1), ANP (SEQ ID NO. 2) or NT-proANP (SEQ ID NO. 3);
(ii) a homologous sequence having at least 70% identity to (i); or
(iii) a fragment of (i) or (ii) which is at least 6 amino acids in length;

and

- 15 (b) (i) pro-BNP (SEQ ID NO. 4), BNP (SEQ ID NO. 5) or NT-proBNP (SEQ ID NO. 6);
(ii) a homologous sequence having at least 70% identity to (i); or
(iii) a fragment of (i) or (ii) which is at least 6 amino acids in length.

20 3. A method according to claim 1 which comprises contacting the sample with

- an agent comprising:

- (a) (i) proANP (SEQ ID NO. 1), ANP (SEQ ID NO. 2) or NT-proANP (SEQ ID NO. 3);
25 (ii) a homologous sequence having at least 70% identity to (i); or
(iii) a fragment of (i) or (ii) which is at least 6 amino acids in length;

and

- (b) (i) pro-BNP (SEQ ID NO. 4), BNP (SEQ ID NO. 5) or NT-proBNP (SEQ ID NO. 6);
30 (ii) a homologous sequence having at least 70% identity to (i); or
(iv) a fragment of (i) or (ii) which is at least 6 amino acids in length;

and

- a first binding substance which is able to bind to:

(a) (i) proANP (SEQ ID NO. 1), ANP (SEQ ID NO. 2) or NT-proANP (SEQ ID NO. 3);

(ii) a homologous sequence having at least 70% identity to (i); or

5 (iii) a fragment of (i) or (ii) which is at least 6 amino acids in length;

and

(b) (i) pro-BNP (SEQ ID NO. 4), BNP (SEQ ID NO. 5) or NT-proBNP (SEQ ID NO. 6);

10 (ii) a homologous sequence having at least 70% identity to (i); or

(iv) a fragment of (i) or (ii) which is at least 6 amino acids in length;

and

(a) the agent.

15 4. A method according to claim 3 wherein the first binding substance comprises:

(a) a bi- or oligo-specific binding substance; or

(b) a mixture of mono-specific binding substances.

20 5. A method according to any one of claims 2 to 4 wherein the first binding substance comprises:

(a) natriuretic receptor GC-A (SEQ ID NO: 27);

(b) homologous sequence having at least 70% identity to (a); or

(c) a fragment of (a) or (b) which is at least 400 amino acids in length.

25

6. A method according to claim 5 wherein the first binding substance comprises an extracellular binding domain of the natriuretic receptor GC-A (SEQ ID NO: 28).

30 7. A method according to any one of claims 2 to 4 wherein the first binding substance comprises an antibody or a fragment or derivative thereof.

8. A method according to claim 7 wherein the antibody comprises a polyclonal antibody, monoclonal antibody, oligoclonal antibody, bifunctional antibody or crossreacting polyclonal antibody.

5 9. A method according to any one of claims 3 to 8 wherein in the agent, (a)(i) is SEQ ID NO. 3 and (b)(i) is SEQ ID NO: 6 or (a)(i) is SEQ ID NO. 2 and (b)(i) is SEQ ID NO. 5.

10 10. A method according to any one of claims 3 to 8 wherein the agent comprises or consists of:

- (a) proBNP₁₅₋₂₄ and proANP₈₂₋₉₆;
- (b) proBNP₁₋₃₇ and proANP₂₉₋₉₈;
- (c) proBNP₁₀₋₂₉ and proANP₂₀₋₈₀.

15 11. A method according to any one of claims 3 to 10 wherein the agent is a polypeptide.

12. A method according to any one of claims 2 to 11 wherein the first binding substance and/or the agent is:

- 20
- (a) labelled with a detectable label; and/or
 - (b) immobilised.

25 13. A method according to any one of claims 2 to 12 which additionally comprises contacting the sample with a second binding substance which is able to bind to the first binding substance.

14. A method according to claim 13 wherein the second binding substance is:

- 30
- (a) labelled with a detectable label; and/or
 - (b) immobilised.

15. A method according to claim 13 wherein the second binding substance causes precipitation of the first binding substance and any peptide which is bound to it.

5 16. A method according to any one of the preceding claims which comprises an immunoassay.

17. A method according to any one of the preceding claims thereby to diagnose heart failure.

10 18. An agent which comprises:

- (a) (i) proANP (SEQ ID NO. 1), ANP (SEQ ID NO. 2) or NT-proANP (SEQ ID NO. 3);
(ii) a homologous sequence having at least 70% identity to (i); or
15 (iii) a fragment of (i) or (ii) which is at least 6 amino acids in length;

and

- (b) (i) pro-BNP (SEQ ID NO. 4), BNP (SEQ ID NO. 5), NT-proBNP (SEQ ID NO. 6);
(ii) a homologous sequence having at least 70% identity to (i); or
20 (iii) a fragment of (i) or (ii) which is at least 6 amino acids in length.

19. An agent according to claim 18 which comprises or consists of:

- (a) proBNP₁₋₃₇ and proANP₂₉₋₉₈;
(b) proBNP₁₅₋₂₄ and proANP₈₂₋₉₆; or
25 (c) proBNP₁₀₋₂₉ and proANP₂₀₋₈₀.

20. An agent according to claim 19 which comprises any one of SEQ ID NOs. 13, 14, 15 or 17.

30 21. An agent according to any one of claims 18 to 20 which is labelled with a detectable label.

22. A polypeptide agent according to any one of claims 18 to 21.

23. A polynucleotide comprising sequence which encodes a polypeptide according to claim 22 or sequence which is complementary to the coding sequence.

5

24. A polynucleotide according to claim 23 which comprises:

- (a) (i) SEQ ID NOs. 7, 8 or 9;
(ii) a sequence complementary to (i);
(iii) a sequence which hybridises under stringent conditions to (i) or (ii);
10 (iv) a sequence which is degenerate as a result of the genetic code to (i),
(ii) or (iii);
(v) a sequence having at least 70% identity to any of the sequences in
(i) to (iv); or

15

and

- (b) (i) SEQ ID NOs. 10, 11 or 12;
(ii) a sequence complementary to (i);
(iii) a sequence which hybridises under stringent conditions to (i) or (ii);
(iv) a sequence which is degenerate as a result of the genetic code to (i),
20 (ii) or (iii);
(v) a sequence having at least 70% identity to any of the sequences in
(i) to (iv); or
(vi) a fragment of any of the sequences in (i) to (v).

25

25. An expression vector comprising a polynucleotide according to claim 23 or 24.

26. A host cell comprising a polynucleotide according to claim 23 or 24 or an expression vector according to claim 25.

30

27. A process for producing a polypeptide according to claim 22 which process comprises:

- (a) cultivating a host cell according to claim 26 under conditions to provide for expression of the polypeptide; and optionally
- (b) recovering the expressed polypeptide.

5 28. A process for producing a polypeptide according to claim 22 which comprises chemical synthesis.

29. A method of identifying a substance that binds specifically to

- 10 (a) (i) proANP (SEQ ID NO. 1), ANP (SEQ ID NO. 2) or NT-proANP (SEQ ID NO. 3);
- (ii) a homologous sequence having at least 70% identity to (i); or
- (iii) a fragment of (i) or (ii) which is at least 6 amino acids in length

and

- 15 (b) (i) pro-BNP (SEQ ID NO. 4), BNP (SEQ ID NO. 5), NT-proBNP (SEQ ID NO. 6);
- (ii) a homologous sequence having at least 70.% identity to (i); or
- (iii) a fragment of (i) or (ii) which is at least 6 amino acids in length

which method comprises:

- 20 (A) contacting a candidate substance with (a) and (b) under conditions which allow specific binding; and
- (B) determining whether the candidate substance binds to (a) and (b).

30. A method according to claim 29 which comprises:

- 25 (a) contacting the candidate substance with an agent according to any one of claims 17 to 21; and
- (b) determining whether the candidate substance binds to the agent.

31. A bi- or oligo- specific antibody, fragment or derivative thereof which is able to bind to both:

- 30 (a) (i) proANP (SEQ ID NO. 1), ANP (SEQ ID NO. 2) or NT-proANP (SEQ ID NO. 3);
- (ii) a homologous sequence having at least 70% identity to (i); or

(iii) a fragment of (i) or (ii) which is at least 6 amino acids in length;
and

- (b) (i) pro-BNP (SEQ ID NO. 4), BNP (SEQ ID NO. 5) or NT-proBNP (SEQ ID NO. 6);
5 (ii) a homologous sequence having at least 70% identity to (i); or
(iii) a fragment of (i) or (ii) which is at least 6 amino acids in length.

32. An antibody, fragment or derivative according to claim 31 which is labelled with a detectable label.

10

33. A process for making an antibody as defined in claim 31 or 32 comprising culturing a cell that expresses the antibody and optionally purifying antibody from the cell.

15

34. A process according to claim 33 in which the cell is one which is obtainable by administering a polypeptide according to claim 22 to a mammal, extracting B cells from the mammal and selecting a cell from these based on the ability to express an antibody with the specificity of the antibody of claim 31.

20

35. A process according to claim 33 in which the cell is recombinant for a polynucleotide which expresses the antibody.

25

36. A dipstick or ELISA plate comprising an antibody according to claim 31 or 32.

30

37. An agent according to any one of claims 17 to 22, a polynucleotide according to claim 23 or 24 or an antibody, fragment or derivative thereof according to claim 31 or 32 for use in treatment of the human or animal body by therapy or diagnosis.

38. Use of a first binding substance as defined in any one of claims 2 to 8, an agent according to any one of claims 18 to 22, a polynucleotide according to claim

23 or 24 or an antibody according to claim 31 to 32 for the manufacture of a medicament for treatment or diagnosis of heart failure.

39. A diagnostic kit comprising:

- 5 (a) a first binding substance as defined in claim 2; or
(b) a first binding substance and an agent as defined in claim 3;
wherein optionally the binding substance and/or the agent is labelled.

40. A kit according to claim 39 wherein the first binding substance is as
10 defined in any one of claims 4 to 8, and/or is present in a dipstick or ELISA plate according to claim 36.

41. A kit according to claim 39 or 40 wherein the agent is as defined in
claims 18 to 22.

15

42. Use of a first binding substance as defined in any one of claims 2 to 8, an agent according to any one of claims 18 to 22, a polynucleotide according to claim 23 or 24, an antibody, fragment or derivative according to claim 31 or 32, a dipstick or ELISA plate according to claim 36 or a kit according to any one of claims 39 to 41
20 in a method for diagnosis or treatment of heart failure.

43. A method of diagnosing or treating heart failure in an individual comprising:

- 25 (a) obtaining a biological sample from an individual;
(b) determining the activation or inactivation of both the ANP and BNP hormonal systems in the individual by a method which comprises detecting the presence or amount of proANP and proBNP or fragments thereof in the sample.

30

44. Use according to claim 42 or a method according to claim 43 which comprises a method as defined in any one of claims 1 to 17.

ABSTRACT**ASSAY**

- 5 An *in vitro* method of determining activation or inactivation of the atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) hormonal systems, the method comprising detecting the presence or amount of atrial and brain natriuretic peptide prohormones (proANP and proBNP) or fragments thereof in a sample.



Figure 1.**Figure 2.**

Figure 3







Figure 4

Figure 5



	Echo CO change	NT-ProANP change	NT-ProBNP change	NT-ProXNP change
Cut-off	> +10%	> -20%	> -20%	> -20%
Positive	9	9	9	11
Negative	2	2	2	0
Sensitivity	81.8	81.8	81.8	100.0